2. 筋萎縮性側索硬化症 [臨床試験数:322,薬物数:365(DrugBank:127),標的遺伝子数:161,標的パスウェイ数:207]
Searched query = "Amyotrophic lateral sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02478450 | December 2020 | 25 March 2019 | Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS): Assessment of Localized Therapeutic Activity by Blinded Observation and Lateral Transplantation (ALTA-BOLT) | Amyotrophic Lateral Sclerosis | Biological: Q-Cells | Q Therapeutics, Inc. | Not recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | ||
2 | NCT02988297 | February 2020 | 16 September 2019 | Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis | Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: RNS60;Drug: Placebo | Revalesio Corporation | Not recruiting | 18 Years | 80 Years | All | 140 | Phase 2 | ||
3 | NCT03651349 | January 2020 | 20 May 2019 | To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers | A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers | Amyotrophic Lateral Sclerosis | Drug: HK-001;Drug: Placebo control | Everfront Biotech Co., Ltd. | Not recruiting | 20 Years | N/A | All | 56 | Phase 1 | Taiwan | |
4 | NCT04098406 | December 2019 | 30 September 2019 | Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS. | Amyotrophic Lateral Sclerosis | Drug: CNM-Au8;Drug: Placebo | Clene Nanomedicine | Clene Australia Pty Ltd | Not recruiting | 40 Years | 80 Years | All | 42 | Phase 2 | Australia |
5 | NCT03127267 | November 2019 | 24 June 2019 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Masitinib (6.0);Drug: Riluzole;Drug: Placebo;Drug: Masitinib (4.5) | AB Science | Not recruiting | 18 Years | 81 Years | All | 495 | Phase 3 | Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT03843710 | October 30, 2019 | 30 September 2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) | A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Gold Nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Not recruiting | 35 Years | 75 Years | All | 24 | Phase 2 | United States |
7 | NCT04066244 | October 23, 2019 | 2 September 2019 | Study of Safety and of the Mechanism of BLZ945 in ALS Patients | An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28 | Amyotrophic Lateral Sclerosis | Drug: BLZ945 | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 20 | Phase 2 | ||
8 | NCT03981536 | October 10, 2019 | 28 October 2019 | A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) | A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: AP-101 | AL-S Pharma | Recruiting | 18 Years | N/A | All | 18 | Phase 1 | Canada | |
9 | NCT04057898 | October 2019 | 9 September 2019 | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by an Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: MN-166;Drug: placebo | MediciNova | Not recruiting | 18 Years | 80 Years | All | 230 | Phase 2/Phase 3 | ||
10 | NCT04082832 | September 30, 2019 | 11 November 2019 | CuATSM Compared With Placebo for Treatment of ALS/MND | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Drug: Cu(II)ATSM;Drug: Placebos | Collaborative Medicinal Development Pty Limited | Recruiting | 18 Years | 75 Years | All | 80 | Phase 2/Phase 3 | Australia | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT03836716 | September 19, 2019 | 30 September 2019 | Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial | Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial | Amyotrophic Lateral Sclerosis | Drug: Arimoclomol | Orphazyme | Recruiting | 18 Years | N/A | All | 231 | Phase 3 | United States;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom | |
12 | NCT04081714 | September 4, 2019 | 30 September 2019 | Intermediate Expanded Access Protocol for ALS | An Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8 | Amyotrophic Lateral Sclerosis | Drug: CNM-Au8 | Clene Nanomedicine | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | Phase 1 | United States | |
13 | NCT03474263 | September 1, 2019 | 25 March 2019 | IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) | A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With | Amyotrophic Lateral Sclerosis | Biological: Biologic: IC14 (monoclonal antibody against human CD14) | Implicit Bioscience | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 2 | Australia;United States | |
14 | NCT04090684 | September 2019 | 30 September 2019 | Ciprofloxacin/Celecoxib Combination in Patients With ALS | Open Label, Off Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Ciprofloxacin/Celecoxib Combination in Patients With ALS | ALS (Amyotrophic Lateral Sclerosis) | Drug: Fixed dose combination Ciprofloxacin/Celecoxib | NeuroSense Therapeutics Ltd. | Not recruiting | 18 Years | 75 Years | All | 30 | Phase 1 | United States | |
15 | NCT04055623 | August 8, 2019 | 30 September 2019 | T-regulatory Cells in ALS | Phase 2a Study of the Expansion and Infusion of Autologous T-Regulatory Cells in Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis) | Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections;Other: Monthly placebo infusions + 3 times per week placebo injections | The Methodist Hospital System | Massachusetts General Hospital;The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston;North East Amyotrophic Lateral Sclerosis Consortium | Recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | NCT03883581 | July 25, 2019 | 4 November 2019 | Impact of Nuedexta on Bulbar Physiology and Function in ALS | Impact of Nuedexta on Bulbar Physiology and Function in ALS | Amyotrophic Lateral Sclerosis | Drug: dextromethorphan HBr and quinidine sulfate | University of Florida | Holy Cross Hospital, Florida;ALS Association | Recruiting | 18 Years | 90 Years | All | 40 | Phase 1/Phase 2 | United States |
17 | NCT03948178 | June 26, 2019 | 16 September 2019 | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS: Open-Label Extension for Patients Completing Study 3119002 | Amyotrophic Lateral Sclerosis | Drug: Levosimendan | Orion Corporation, Orion Pharma | Recruiting | 18 Years | 120 Years | All | 450 | Phase 3 | Spain | |
18 | NCT04140136 | June 17, 2019 | 4 November 2019 | The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) | The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) : A Pilot Exploratory Study | Amyotrophic Lateral Sclerosis | Dietary Supplement: Tocotrienols;Dietary Supplement: Placebo | University of Malaya | Recruiting | N/A | N/A | All | 20 | Phase 2 | Malaysia | |
19 | NCT03945279 | May 30, 2019 | 4 November 2019 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: BIIB100;Drug: Placebo | Biogen | Recruiting | 18 Years | N/A | All | 40 | Phase 1 | United States | |
20 | JPRN-jRCTs041190028 | 23/05/2019 | 22 July 2019 | Ivig for ALS | Intravenous Immunoglobulin Therapy for Amyotrophic lateral sclerosis - ALSIvig | Amyotrophic lateral sclerosis ALS | Treatment of Intravenous immunoglobulin at a dose of 400 mg/kg/day for 5 days. | Makoto Matsui | Recruiting | >=30 age old | <80 age old | Both | 30 | N/A | none | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
21 | NCT03537807 | May 13, 2019 | 26 August 2019 | Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS) | BHV-0223 Expanded Access Protocol in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;ALS;Lou Gehrig Disease;Lou Gehrig's Disease;Lou-Gehrigs Disease;Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Drug: Riluzole | Biohaven Pharmaceuticals, Inc. | Not recruiting | 18 Years | N/A | All | Phase 2 | |||
22 | NCT03929068 | May 13, 2019 | 15 July 2019 | Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis | Sinemet in ALS and PLS | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: carbidopa-levodopa;Drug: Placebo Oral Tablet | Washington University School of Medicine | Recruiting | 18 Years | N/A | All | 15 | Phase 1 | United States | |
23 | JPRN-JMA-IIA00419 | 29/03/2019 | 23 April 2019 | Phase 1 dose-escalation study of bosutinib in patients with amyotrophic lateral sclerosis (ALS) | Phase 1 dose-escalation study of bosutinib in patients with amyotrophic lateral sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Intervention type:DRUG. Intervention1:Medicine, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:The study consists of a 12-week observation period, a 1-week (5- to 9-day) transitional period, a 12-week study treatment period, and a 4-week follow-up period. . | Center for iPS Cell Research and Application (CiRA), Kyoto University | Recruiting | >=20 YEARS | <80 YEARS | BOTH | 24 | Phase 1 | Japan | |
24 | JPRN-UMIN000036295 | 2019/03/29 | 16 July 2019 | Phase 1 Dose Escalation Study of Bosutinib in Patients with Amyotrophic Lateral Sclerosis (ALS) | Phase 1 Dose Escalation Study of Bosutinib in Patients with Amyotrophic Lateral Sclerosis (ALS) - Phase 1 Dose Escalation Study of Bosutinib in Patients with Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | The study consists of a 12-week observation period, a 1-week (5- to 9-day) transitional period, a 12-week study treatment period, and a 4-week follow-up period. 3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose levels [100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. | Center for iPS Cell Research and Application, Kyoto University | Provider of the investigational product: Pfizer Japan Inc. | Recruiting | 20years-old | 80years-old | Male and Female | 24 | Phase 1 | Japan |
25 | JPRN-jRCT2051190001 | 29/03/2019 | 22 July 2019 | Phase 1 Dose Escalation Study of Bosutinib in Patients with Amyotrophic Lateral Sclerosis (ALS) | Phase 1 Dose Escalation Study of Bosutinib in Patients with Amyotrophic Lateral Sclerosis (ALS) - Phase 1 Dose Escalation Study of Bosutinib in Patients with Amyotrophic Lateral Sclerosis (ALS) | amyotrophic lateral sclerosis ALS | The study consists of a 12-week observation period, a 1-week (5- to 9-day) transitional period, a 12-week study treatment period, and a 4-week follow-up period. 3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose levels [100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. | Haruhisa Inoue | Recruiting | 20 age old | 79 age old | Both | 24 | Phase 1 | none | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
26 | NCT03800524 | February 22, 2019 | 28 October 2019 | Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS | Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Tauroursodeoxycholic Acid;Drug: Placebo | Humanitas Mirasole SpA | University of Ulm;University of Sheffield;University Hospital, Tours;KU Leuven;UMC Utrecht;University of Dublin, Trinity College;Bruschettini S.r.l.;Istituto Superiore di Sanità;Motor Neurone Disease Association;European Commission | Recruiting | 18 Years | 80 Years | All | 440 | Phase 3 | Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom |
27 | NCT03792490 | February 20, 2019 | 25 March 2019 | Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | Amyotrophic Lateral Sclerosis | Drug: Fasudil;Drug: Placebo | University Medical Center Goettingen | Recruiting | 18 Years | N/A | All | 120 | Phase 2 | Germany | |
28 | NCT03766321 | February 2019 | 18 December 2018 | Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients | Interplay Between Gut Microbiota and Adaptive Immunity in Amyotrophic Lateral Sclerosis: a Clinical Trial | Amyotrophic Lateral Sclerosis | Biological: Fecal microbiota transplantation;Biological: Placebo | Azienda Ospedaliero-Universitaria di Modena | University of Modena and Reggio Emilia;Catholic University of the Sacred Heart;Campus Bio-Medico University;Azienda Ospedaliero-Universitaria Careggi;Azienda Ospedaliera di Perugia;University of Chieti;University of Florence | Not recruiting | 18 Years | 70 Years | All | 42 | N/A | Italy |
29 | NCT03293069 | January 30, 2019 | 3 June 2019 | Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis | Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone | Amyotrophic Lateral Sclerosis | Drug: Deferiprone;Drug: Placebo Oral Tablet | University Hospital, Lille | Ministry of Health, France | Recruiting | 18 Years | 75 Years | All | 240 | Phase 2/Phase 3 | France |
30 | NCT03693781 | January 30, 2019 | 28 January 2019 | Colchicine for Amyotrophic Lateral Sclerosis | Colchicine for Amyotrophic Lateral Sclerosis: a Phase II, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial | Amyotrophic Lateral Sclerosis | Drug: Colchicine 1 MG Oral Tablet;Drug: Placebo Oral Tablet | Azienda Ospedaliero-Universitaria di Modena | University of Modena and Reggio Emilia;University of Turin, Italy;Istituto Auxologico Italiano;IRCCS National Neurological Institute C. Mondino Foundation;University of Bari;IRCCS San Raffaele;University of Padova;University of Milan;Istituto Di Ricerche Farmacologiche Mario Negri;University of Campania Luigi Vanvitelli;Catholic University of the Sacred Heart | Not recruiting | 18 Years | 80 Years | All | 54 | Phase 2 | Italy |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
31 | NCT03690791 | January 9, 2019 | 25 February 2019 | Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease | A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (CannTrust CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patients | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: CannTrust CBD Oil (capsule);Drug: Placebo (capsule) | Gold Coast Hospital and Health Service | CannTrust Inc. | Recruiting | 25 Years | 75 Years | All | 30 | Phase 3 | Australia |
32 | NCT03757351 | December 28, 2018 | 30 September 2019 | Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: DNL747;Drug: Placebo | Denali Therapeutics Inc. | Recruiting | 21 Years | 80 Years | All | 16 | Phase 1 | United States;Netherlands | |
33 | NCT03755167 | December 9, 2018 | 30 September 2019 | A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV | An Open-Label, Multi-Center, Follow up Study to Protocol 101/2 - Continued Treatment by Intravenously Administered IPL344 to Amyotrophic Lateral Sclerosis (ALS) Patients | Amyotrophic Lateral Sclerosis (ALS) | Drug: IPL344 | Immunity Pharma Ltd. | Recruiting | 18 Years | 75 Years | All | 15 | Phase 2 | Israel | |
34 | JPRN-JMA-IIA00397 | 05/12/2018 | 7 October 2019 | Phase 1/2a Study of Ropinirole Hydrochloride Extended-Release Tablets in Patients with Amyotrophic Lateral Sclerosis (ALS) | Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets -Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)- | amyotrophic lateral sclerosis (ALS) | Intervention type:DRUG. Intervention1:Requip CR tablets, Dose form:SUSTAINED-RELEASE TABLET, Route of administration:ORAL, intended dose regimen:Once daily ropinirole hydrochloride extended-release tablet with dose-escalation tolerable from 2mg to 16mg for 24 weeks (Interventions). Control intervention1:Placebo, Dose form:SUSTAINED-RELEASE TABLET, Route of administration:ORAL, Intended dose regimen:Once daily placebo tablet with dose-escalation tolerable from 2mg to 16mg for 24 weeks (Interventions). | Satoru Morimoto | Not Recruiting | >=20 YEARS | <=80 YEARS | BOTH | 20 | Phase 1-2 | Japan | |
35 | NCT03793868 | December 4, 2018 | 14 January 2019 | Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis | Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Perampanel;Other: Placebo | Mayo Clinic | Recruiting | 18 Years | 70 Years | All | 24 | Early Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
36 | NCT03944447 | December 1, 2018 | 7 October 2019 | Outcomes Mandate National Integration With Cannabis as Medicine | Outcomes Mandate National Integration With Cannabis as Medicine | Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder | Drug: Cannabis, Medical | OMNI Medical Services, LLC | Recruiting | 7 Years | N/A | All | 100000 | Phase 2 | United States | |
37 | EUCTR2018-000137-13-NL | 21/11/2018 | 28 February 2019 | A study to compare the use of Arimoclomol with placebo in patients with Amyotrophic Lateral Sclerosis | A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Arimoclomol Product Code: BRX-345 Pharmaceutical Form: Capsule, hard INN or Proposed INN: ARIMOCLOMOL CAS Number: 368860-21-3 Current Sponsor code: BRX-345 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Orphazyme A/S | Authorised | Female: yes Male: yes | 231 | Phase 3 | France;United States;Canada;Poland;Belgium;Spain;Germany;Netherlands;Italy;United Kingdom;Switzerland;Sweden | |||
38 | NCT02118727 | November 7, 2018 | 11 November 2019 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS | Amyotrophic Lateral Sclerosis;Frontal Temporal Dementia | Drug: Memantine;Drug: Placebo (for Memantine) | University of Kansas Medical Center | Recruiting | 18 Years | 85 Years | All | 90 | Phase 2 | United States | |
39 | NCT03580616 | October 24, 2018 | 28 January 2019 | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study | Amyotrophic Lateral Sclerosis;Possible Amyotrophic Sclerosis | Drug: L-Serine | Elijah W. Stommel | Brain Chemistry Labs, Institute for Ethnomedicine | Recruiting | 18 Years | N/A | All | 50 | Phase 2 | United States |
40 | EUCTR2017-004459-21-IT | 11/09/2018 | 12 November 2018 | Study evaluating the treatment with colchicine for the amyotrophic lateral sclerosis | Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial - Co-ALS | Definite or probable amyotrophic lateral sclerosis MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10052889 Term: ALS System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE Product Name: Colchicina Product Code: Colchicina Pharmaceutical Form: Tablet INN or Proposed INN: COLCHICINA CAS Number: 64-86-8 Current Sponsor code: Colchicina Other descriptive name: COLCHICINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- | AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA | Authorised | Female: yes Male: yes | 54 | Phase 2 | Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
41 | NCT03626012 | September 10, 2018 | 4 November 2019 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: BIIB078;Drug: Placebo | Biogen | Not recruiting | 18 Years | N/A | All | 80 | Phase 1 | United States;Canada;Netherlands;United Kingdom | |
42 | NCT03508453 | August 15, 2018 | 9 July 2018 | IC14 for Treatment of Amyotrophic Lateral Sclerosis | A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14 for Treatment of Patients With Rapidly Progressive Motor Neuron Disease | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Biological: IC14;Other: Placebo | Implicit Bioscience | Not recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | Australia | |
43 | NCT03652805 | August 1, 2018 | 30 September 2019 | A Study of IPL344 in the Treatment of ALS Patients | Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: IPL344 | Immunity Pharma Ltd. | Recruiting | 18 Years | 80 Years | All | 15 | Phase 1/Phase 2 | Israel | |
44 | NCT03491462 | July 31, 2018 | 15 July 2019 | Arimoclomol in Amyotropic Lateral Sclerosis | A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Arimoclomol;Drug: Placebo oral capsule | Orphazyme | Not recruiting | 18 Years | N/A | All | 231 | Phase 3 | United States;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;Denmark | |
45 | NCT03506425 | June 21, 2018 | 23 April 2019 | A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) | A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) | ALS | Drug: Triheptanoin | Richard Bedlack, M.D., Ph.D. | Ultragenyx Pharmaceutical Inc | Not recruiting | 18 Years | N/A | All | 10 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
46 | NCT03472950 | June 11, 2018 | 24 June 2019 | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis | ALS | Drug: Ranolazine 500 MG;Drug: Ranolazine 1000 MG | University of Kansas Medical Center | Gilead Sciences | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
47 | EUCTR2017-002754-36-BE | 15/05/2018 | 20 August 2018 | Effects of oral Levosimendan on breathing function in patients with the disease Amyotrophic Lateral Sclerosis (ALS) | Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS - REFALS | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 Pharmaceutical Form: Capsule INN or Proposed INN: LEVOSIMENDAN CAS Number: 141505-33-1 Current Sponsor code: ODM-109 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Orion Corporation | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;Canada;Belgium;Australia;Germany;Netherlands;Sweden | |||
48 | EUCTR2017-005065-47-SE | 15/05/2018 | 3 September 2018 | A single-center, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis. | A single-centre, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS);Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: ILB Product Code: ILB Pharmaceutical Form: Solution for injection INN or Proposed INN: ILB CAS Number: 9011-18-1 Other descriptive name: DEXTRAN SULFATE SODIUM Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | TikoMed AB | Authorised | Female: yes Male: yes | 15 | Phase 2 | Sweden | |||
49 | EUCTR2018-000142-18-FI | 09/05/2018 | 21 May 2018 | Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative care | Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.1 Level: LLT Classification code 10036704 Term: Primary lateral sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dexdor Pharmaceutical Form: Concentrate for concentrate for solution for infusion INN or Proposed INN: DEXMEDETOMIDINE CAS Number: 113775-47-6 Trade Name: Ketanest-S Pharmaceutical Form: Infusion INN or Proposed INN: ESKETAMINE CAS Number: 33643-46-8 | Turku University Hospital | Authorised | Female: yes Male: yes | 20 | Phase 4 | Finland | |||
50 | EUCTR2017-002754-36-ES | 29/04/2018 | 14 May 2018 | Effects of oral Levosimendan on breathing function in patients with the disease Amyotrophic Lateral Sclerosis (ALS) | Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS - REFALS | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 Pharmaceutical Form: Capsule INN or Proposed INN: LEVOSIMENDAN CAS Number: 141505-33-1 Current Sponsor code: ODM-109 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Orion Corporation | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;Canada;Belgium;Australia;Germany;Netherlands;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
51 | EUCTR2017-002754-36-FI | 19/04/2018 | 25 June 2018 | Effects of oral Levosimendan on breathing function in patients with the disease Amyotrophic Lateral Sclerosis (ALS) | Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS - REFALS | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 Pharmaceutical Form: Capsule INN or Proposed INN: LEVOSIMENDAN CAS Number: 141505-33-1 Current Sponsor code: ODM-109 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Orion Corporation | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;Canada;Belgium;Australia;Germany;Netherlands;Sweden | |||
52 | EUCTR2017-002754-36-AT | 17/04/2018 | 23 July 2018 | Effects of oral Levosimendan on breathing function in patients with the disease Amyotrophic Lateral Sclerosis (ALS) | Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS - REFALS | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Oral LEVOSIMENDAN Product Code: ODM-109 Pharmaceutical Form: Capsule INN or Proposed INN: LEVOSIMENDAN CAS Number: 141505-33-1 Current Sponsor code: ODM-109 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Orion Corporation | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;Canada;Belgium;Australia;Germany;Netherlands;Sweden | |||
53 | NCT03482050 | April 12, 2018 | 20 August 2018 | A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS) | ALS (Amyotrophic Lateral Sclerosis) | Biological: AstroRx | Kadimastem | Recruiting | 18 Years | 70 Years | All | 21 | Phase 1/Phase 2 | Israel | |
54 | NCT03334786 | April 5, 2018 | 10 September 2018 | Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS | An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis;Fasciculation | Drug: FLX-787-ODT | Flex Pharma, Inc. | Not recruiting | 18 Years | N/A | All | 3 | Phase 1/Phase 2 | United States | |
55 | NCT03679975 | April 4, 2018 | 4 February 2019 | Riluzole Oral Soluble Film Swallowing Safety in Amyotrophic Lateral Sclerosis | A Single Center Study to Evaluate the Effect of Riluzole Oral Soluble Film on Swallowing Safety in Individuals With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Riluzole Oral Soluble film (ROSF) 50 mg | Aquestive Therapeutics | inVentiv Health Clinical;Covance | Not recruiting | 18 Years | 80 Years | All | 9 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
56 | NCT03488524 | March 29, 2018 | 26 August 2019 | Open Label Extension Study of AMX0035 in Patients With ALS | Open Label Extension Study of AMX0035 in Patients With ALS | Amyotrophic Lateral Sclerosis;ALS | Drug: AMX0035 | Amylyx Pharmaceuticals Inc. | Massachusetts General Hospital Neurology Clinical Research Institute | Recruiting | N/A | N/A | All | 132 | Phase 2 | United States |
57 | NCT03457753 | March 1, 2018 | 27 May 2019 | Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis | A Multi-Center, Open Label Study to Assess the Safety and Tolerability of Riluzole Oral Soluble Film in Subjects With Amyotrophic Lateral Sclerosis Over 12 Weeks of Twice Daily Treatment. | ALS | Drug: Riluzole Oral Soluble Film | Aquestive Therapeutics | Inventiv Health;Covance | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 2 | United States |
58 | NCT03520517 | February 2, 2018 | 2 September 2019 | Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS | Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;ALS;Lou Gehrig Disease;Lou Gehrig's Disease;Lou-Gehrigs Disease;Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Drug: BHV-0223 | Biohaven Pharmaceuticals, Inc. | Cognitive Research Corporation | Not recruiting | 18 Years | N/A | All | 22 | Phase 1 | United States |
59 | NCT03427086 | January 29, 2018 | 15 July 2019 | Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis | Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Biotin;Drug: Placebo Oral Tablet | American University of Beirut Medical Center | Recruiting | 18 Years | 80 Years | All | 30 | Phase 2 | Lebanon | |
60 | NCT03136809 | January 18, 2018 | 11 November 2019 | ALS Treatment Extension Study | A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001 | Amyotrophic Lateral Sclerosis | Drug: Cu(II)ATSM | Collaborative Medicinal Development Pty Limited | Not recruiting | 18 Years | 75 Years | All | 28 | Phase 1/Phase 2 | Australia | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
61 | NCT03377309 | December 1, 2017 | 8 January 2018 | Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients | Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients | Amyotrophic Lateral Sclerosis | Drug: Fycompa | American University of Beirut Medical Center | Recruiting | 18 Years | 80 Years | All | 20 | Phase 2 | Lebanon | |
62 | NCT03548311 | November 1, 2017 | 2 July 2018 | Clinical Trial of Ultra-high Dose Methylcobalamin for ALS | Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study | Amyotrophic Lateral Sclerosis | Drug: saline solution;Drug: methylcobalamin | University of Tokushima | Eisai Co., Ltd. | Recruiting | 20 Years | N/A | All | 128 | Phase 3 | Japan |
63 | NCT03338114 | November 2017 | 29 January 2018 | Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS | An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis;Fasciculation | Drug: FLX-787-ODT (orally disintigrating tablet) | Flex Pharma, Inc. | Not recruiting | 18 Years | N/A | All | 0 | Phase 1/Phase 2 | United States | |
64 | NCT03272503 | October 27, 2017 | 22 October 2019 | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II Randomized, Placebo-Controlled, Double Blinded, Multi-Centre Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis | ALS;Amyotrophic Lateral Sclerosis | Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation);Drug: Placebo Oral Tablet | University of Calgary | ALS Canada;Brain Canada | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | Canada |
65 | NCT03268603 | October 10, 2017 | 23 April 2019 | Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) | A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis | ALS;Amyotrophic Lateral Sclerosis | Drug: Autologous Adipose-derived Mesenchymal Stromal Cells | Mayo Clinic | State of Minnesota Regenerative Medicine Minnesota | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
66 | NCT03168711 | October 1, 2017 | 3 December 2018 | Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) | Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Inosine;Drug: Placebo | Massachusetts General Hospital | The Salah Foundation;MGH cure ALS Fund | Recruiting | 18 Years | 85 Years | All | 30 | Phase 2 | United States |
67 | NCT03487263 | October 1, 2017 | 25 March 2019 | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | Motor Neuron Disease;Amyotrophic Lateral Sclerosis | Biological: IC14 | Implicit Bioscience | Royal Brisbane and Women's Hospital | Not recruiting | 18 Years | 75 Years | All | 10 | Phase 1 | Australia |
68 | NCT03359538 | September 19, 2017 | 16 December 2017 | Rapamycin Treatment for ALS | Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Rapamycin;Drug: Placebo Oral Tablet | Azienda Ospedaliera - Universitaria di Modena | University of Modena and Reggio Emilia;Azienda Ospedaliero Universitaria Maggiore della Carita;IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy;University of Turin, Italy;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta;Azienda Ospedaliera Niguarda Cà Granda;Fondazione Salvatore Maugeri;University of Padova | Recruiting | 18 Years | 75 Years | All | 63 | Phase 2 | Italy |
69 | NCT03280056 | August 28, 2017 | 4 November 2019 | Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients | A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS | Amyotrophic Lateral Sclerosis (ALS) | Biological: NurOwn® (MSC-NTF cells);Other: Placebo | Brainstorm-Cell Therapeutics | California Institute for Regenerative Medicine (CIRM) | Not recruiting | 18 Years | 60 Years | All | 261 | Phase 3 | United States |
70 | NCT03707795 | August 21, 2017 | 25 March 2019 | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Familial Amyotrophic Lateral Sclerosis | Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | University of Kentucky | Recruiting | 20 Years | 80 Years | All | 30 | Early Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
71 | NCT03237741 | August 7, 2017 | 11 June 2018 | Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants | A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential | Amyotrophic Lateral Sclerosis | Drug: Reference capsule GDC-0134;Drug: Prototype capsule GDC-0134;Drug: rabeprazole | Genentech, Inc. | Quotient Clinical | Not recruiting | 30 Years | 65 Years | Female | 24 | Phase 1 | United Kingdom |
72 | NCT03160898 | July 24, 2017 | 15 April 2019 | A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: CK-2127107;Drug: Placebo | Cytokinetics | Astellas Pharma Inc | Not recruiting | 18 Years | 80 Years | All | 458 | Phase 2 | United States;Australia;Canada;Ireland;Netherlands;Spain |
73 | JPRN-UMIN000029308 | 2017/07/18 | 2 April 2019 | Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of patients with amyotrophic lateral sclerosis with febuxostat and inosine in combination. | Amyotrophic lateral sclerosis | Febuxostat 20 mg, Inosine 500 mg, twice a day for 14 days | Teikyo University | Not Recruiting | 20years-old | 80years-old | Male and Female | 3 | Not applicable | Japan | ||
74 | EUCTR2016-002399-28-IT | 14/07/2017 | 29 January 2018 | Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis | Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis - RAP.ALS | definite or probable ALS MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE Product Name: Rapamune Pharmaceutical Form: Coated tablet | AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA | Authorised | Female: yes Male: yes | 63 | Phase 2 | Italy | |||
75 | NCT03186040 | July 13, 2017 | 26 August 2019 | Open-label Clinical Trial of Lacosamide in ALS | Open-label Clinical Trial: Safety of Lacosamide in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Lacosamide | Chiba University | Recruiting | 20 Years | N/A | All | 30 | Phase 1/Phase 2 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
76 | JPRN-jRCTs031180173 | 07/07/2017 | 10 September 2019 | Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis | Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis | amyotrophic lateral sclerosis amyotrophic lateral sclerosis;G122 | gradual increase of lacosamide from 100mg to 400mg for 4 weeks | Satoshi Kuwabara | Recruiting | 20age | unrestricted | Both | 30 | Phase 1-2 | none | |
77 | NCT02588807 | July 2017 | 16 December 2017 | Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis | The Combination of Phospholipids and Medical Herbs for the Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS); A Pilot Study | Amyotrophic Lateral Sclerosis | Drug: Spirit1 | Herb Spirit | Carmel Medical Center | Not recruiting | 18 Years | 75 Years | All | 10 | Phase 1 | |
78 | NCT03068754 | June 22, 2017 | 28 October 2019 | Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) | A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Acthar;Drug: Placebo | Mallinckrodt | Not recruiting | 18 Years | 75 Years | All | 143 | Phase 2/Phase 3 | United States;Argentina;Canada;Chile;Colombia;Mexico;Peru | |
79 | NCT03127514 | June 22, 2017 | 22 October 2019 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS | Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Diseases;Neurodegenerative Diseases;Spinal Cord Diseases;TDP-43 Proteinopathies;Nervous System Diseases;Central Nervous System Diseases | Drug: AMX0035;Other: Placebo | Amylyx Pharmaceuticals Inc. | ALS Finding a Cure Foundation;ALS Association;Northeast ALS Consortium;Massachusetts General Hospital Neurology Clinical Research Institute;Leandro P. Rizzuto Foundation | Not recruiting | 18 Years | 80 Years | All | 132 | Phase 2 | United States |
80 | NCT03039673 | June 19, 2017 | 11 November 2019 | MIROCALS: Modifying Immune Response and OutComes in ALS | Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial | Amyotrophic Lateral Sclerosis | Drug: Riluzole;Drug: IL-2;Drug: 5% glucose water solution | Centre Hospitalier Universitaire de Nimes | Not recruiting | 18 Years | 75 Years | All | 304 | Phase 2 | France;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
81 | JPRN-UMIN000027476 | 2017/06/01 | 16 July 2019 | Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis | Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis - Open-label clinical trial of lacosamide in ALS | amyotrophic lateral sclerosis | gradual increase of lacosamide from 100mg to 400mg for 4 weeks | Department of Neurology Chiba University Hospital | Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan | |
82 | NCT03324399 | June 1, 2017 | 15 July 2019 | A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS | A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis;ALS | Dietary Supplement: probiotic | Avera McKennan Hospital & University Health Center | Not recruiting | 18 Years | N/A | All | 5 | N/A | United States | |
83 | NCT02962050 | May 31, 2017 | 4 November 2019 | Delineating Swallowing Impairment and Decline in ALS | Delineating Physiologic Mechanisms of Swallowing Impairment and Decline in ALS | Amyotrophic Lateral Sclerosis | Procedure: Videofluoroscopic Swallowing Study (VFSS);Procedure: High Resolution Manometry;Other: DIGEST;Other: Penetration Aspiration Scale;Other: Normalized Residue Ratio Scale;Device: Voluntary Peak Cough Flow Testing;Device: Iowa Oral Performance Instrument;Drug: Capsaicin Challenge;Device: Pulmonary Function Testing;Other: Eating Assessment Tool 10;Other: The Center for Neurologic Study Bulbar Function Scale | University of Florida | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 18 Years | 90 Years | All | 110 | N/A | United States |
84 | JPRN-UMIN000025614 | 2017/04/24 | 2 April 2019 | Perampanel for sporadic amyotrophic lateral sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial | Perampanel for sporadic amyotrophic lateral sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial - Perampanel for sporadic amyotrophic lateral sclerosis (ALS) | Sporadic amyotrophic lateral sclerosis | Once daily perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks (Interventions) Once daily perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks (Interventions). Once daily placebo for 48 weeks (Control) | Department of Neurology, Tokyo Medical University | Not Recruiting | 40years-old | 78years-old | Male and Female | 60 | Phase 2 | Japan | |
85 | NCT03019419 | April 24, 2017 | 5 November 2018 | Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) | Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials | ALS | Drug: placebo;Drug: Perampanel | Tokyo Medical University | Not recruiting | 40 Years | 78 Years | All | 60 | Phase 2 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
86 | NCT03103815 | April 24, 2017 | 16 December 2017 | Trial of Amivita in Amyotrophic Lateral Sclerosis | Trial of Amivita in Amyotrophic Lateral Sclerosis: a Single-center, Single-blind, Self-controlled Clinical Trial | Amyotrophic Lateral Sclerosis | Drug: Amivita | Wujin People's Hospital | Nanjing 1718 Biotech Co. Ltd | Recruiting | 18 Years | 70 Years | All | 30 | N/A | China |
87 | NCT03049046 | April 7, 2017 | 16 December 2017 | CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS | Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS | Amyotrophic Lateral Sclerosis | Drug: CC100;Drug: Placebos | Chemigen, LLC | Recruiting | 18 Years | 64 Years | All | 21 | Phase 1 | United States | |
88 | NCT02943850 | April 1, 2017 | 22 October 2018 | CNS10-NPC-GDNF for the Treatment of ALS | Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: Stem cell (HPC) implantation;Device: Stereotactic surgical device | Cedars-Sinai Medical Center | California Institute for Regenerative Medicine | Not recruiting | 18 Years | N/A | All | 18 | Phase 1 | United States |
89 | NCT03272802 | March 16, 2017 | 8 April 2019 | Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) | Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population | Neuromuscular Diseases | Drug: Edaravone;Drug: Riluzole | Isfahan University of Medical Sciences | Not recruiting | 18 Years | 75 Years | All | 20 | Phase 2/Phase 3 | Iran, Islamic Republic of | |
90 | NCT03070119 | March 8, 2017 | 26 August 2019 | Long-Term Evaluation of BIIB067 | An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Drug: BIIB067 | Biogen | Ionis Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | All | 48 | Phase 3 | United States;Belgium;Canada;Germany;United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
91 | JPRN-UMIN000026221 | 2017/03/02 | 2 April 2019 | Safety of perampanel in patients with motor neuron disease | amyotrophic lateral sclerosis | Once daily perampanel with dose escalation from 2mg to 8mg. | Department of Neurology, Juntendo University School of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 15 | Phase 1 | Japan | ||
92 | NCT03214146 | February 1, 2017 | 27 May 2019 | Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS | An Open-label, Phase 1 Trial for Safety and Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS) | Amyotrophic Lateral Sclerosis | Biological: HYNRCS-Allo inj | Hanyang University Seoul Hospital | Corestem, Inc. | Not recruiting | 25 Years | 80 Years | All | 6 | Phase 1 | Korea, Republic of |
93 | NCT03020797 | December 2016 | 17 September 2018 | A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Placebo Oral Tablet;Drug: Perampanel | Stony Brook University | Eisai Inc. | Recruiting | 18 Years | 80 Years | All | 60 | N/A | United States | |
94 | NCT03456882 | November 18, 2016 | 4 November 2019 | The Effect of RNS60 on ALS Biomarkers | The Effect of RNS60 on ALS Biomarkers | Amyotrophic Lateral Sclerosis | Drug: RNS60 | Mario Negri Institute for Pharmacological Research | ALS Association;Get out ONLUS | Recruiting | 18 Years | 80 Years | All | 142 | Phase 2 | United States;Italy |
95 | JPRN-UMIN000024854 | 2016/11/16 | 2 April 2019 | Clinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosis | Amyotrophic Lateral Sclerosis (ALS) | Edaravone treatment for ALS patients | Okayama university | Recruiting | 20years-old | 75years-old | Male and Female | 20 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
96 | NCT02870634 | November 16, 2016 | 11 November 2019 | Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND | A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: Cu(II)ATSM | Collaborative Medicinal Development Pty Limited | Not recruiting | 18 Years | 75 Years | All | 50 | Phase 1 | Australia | |
97 | NCT02781454 | October 2016 | 20 August 2018 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS) | Sporadic Amyotrophic Lateral Sclerosis | Drug: Mexiletine;Drug: Placebo | University of Washington | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States |
98 | NCT02868580 | October 2016 | 2 September 2019 | Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). | Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project. | Amyotrophic Lateral Sclerosis | Drug: Triumeq | Neuroscience Trials Australia | Macquarie University, Australia;Westmead Hosptial;Calvary Health Care Bethlehem;The University of Sydney - Brain and Mind Centre | Not recruiting | 18 Years | 75 Years | All | 43 | Phase 2 | Australia |
99 | NCT02936635 | October 2016 | 16 December 2017 | A Study for Patients Who Completed VITALITY-ALS (CY 4031) | A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031) | Amyotrophic Lateral Sclerosis (ALS) | Drug: tirasemtiv | Cytokinetics | Not recruiting | 18 Years | N/A | All | 280 | Phase 3 | United States;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom | |
100 | JPRN-UMIN000024312 | 2016/09/20 | 2 April 2019 | Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. | Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis | Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks | Tsukuba International Clinical Pharmacology Clinic | Not Recruiting | 20years-old | 80years-old | Male and Female | 12 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
101 | NCT03067857 | September 2016 | 18 June 2018 | Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease | Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease | Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy;Progressive Bulbar Palsies | Biological: Stem Cells | Stem Cells Arabia | Not recruiting | 24 Years | 70 Years | All | 40 | Phase 1/Phase 2 | ||
102 | NCT02794857 | August 29, 2016 | 11 June 2018 | Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation | Amyotrophic Lateral Sclerosis | Drug: NP001;Drug: Placebo | Neuraltus Pharmaceuticals, Inc. | Not recruiting | 21 Years | 80 Years | All | 138 | Phase 2 | United States;Canada | |
103 | NCT02872142 | August 29, 2016 | 26 August 2019 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Patients With Amyotrophic Lateral Sclerosis | Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein® 5% in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: Albutein 5% | Grifols Therapeutics LLC | Grifols Biologicals, LLC | Not recruiting | 19 Years | 69 Years | All | 12 | Phase 2 | United States |
104 | EUCTR2015-005347-14-GB | 25/08/2016 | 10 September 2018 | Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients | Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placebo- controlled, phase-II Proof of Concept/ Proof of Mechanism Clinical Trial - MIROCALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Proleukin 18 MUI Product Name: proleukin Pharmaceutical Form: Solution for infusion in pre-filled syringe Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Subcutaneous use | CHU DE NIMES | Authorised | Female: yes Male: yes | 216 | Phase 2 | United Kingdom | |||
105 | NCT03114215 | June 29, 2016 | 17 June 2019 | Effect of MD1003 in Amyotrophic Lateral Sclerosis | Effect of MD1003 in Amyotrophic Lateral Sclerosis: a Randomized Double Blind Placebo Controlled Pilot Study | ALS;Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: MD1003;Drug: Placebo oral capsule | MedDay Pharmaceuticals SA | Not recruiting | 25 Years | 80 Years | All | 30 | Phase 2 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
106 | NCT03876002 | June 28, 2016 | 8 April 2019 | Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET | Evaluation of Microglial Activation Using the PET Imaging Ligand [18F]PBR06 in Patients With Amyotrophic Lateral Sclerosis Compared to Healthy Volunteers | Healthy Volunteers;Amyotrophic Lateral Sclerosis | Drug: [18F]PBR06 | Molecular NeuroImaging | Not recruiting | 18 Years | 80 Years | All | 23 | Phase 1 | United States | |
107 | NCT03835507 | June 20, 2016 | 25 February 2019 | Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis | Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: recombinant human erythropoietin(rhEPO) | Hanyang University Seoul Hospital | Recruiting | 25 Years | 80 Years | All | 64 | Phase 1/Phase 2 | Korea, Republic of | |
108 | EUCTR2015-005810-31-FR | 03/06/2016 | 31 October 2016 | Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study | Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study - MD1003-ALS | Amyotrophic lateral sclerosis MedDRA version: 19.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | MEDDAY PHARMACEUTICALS | Authorised | Female: yes Male: yes | Phase 2 | France | ||||
109 | NCT02655614 | May 31, 2016 | 28 October 2019 | A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis | A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: GDC-0134;Drug: Placebo;Drug: Rabeprazole;Drug: Midazolam;Drug: Caffeine | Genentech, Inc. | Not recruiting | 18 Years | N/A | All | 82 | Phase 1 | United States;Canada;Netherlands | |
110 | NCT03241784 | May 16, 2016 | 11 June 2018 | T-Regulatory Cells in Amyotrophic Lateral Sclerosis | Expansion and Infusion of T-Regulatory Cells in Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis) | Biological: Autologous T-regulatory lymphocytes;Biological: Interleukin-2 | Stanley H. Appel, MD | Not recruiting | 18 Years | N/A | All | 4 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
111 | NCT02709330 | April 2016 | 16 December 2017 | ALS Reversals - Lunasin Regimen | An Open-label, Single-center, 12-month Trial of a Lunasin Regimen for Patients With Amyotrophic Lateral Sclerosis (ALS) | ALS (Amyotrophic Lateral Sclerosis) | Drug: Lunasin Regimen;Other: Historical control | Richard Bedlack, M.D., Ph.D. | Not recruiting | 18 Years | N/A | All | 50 | Phase 2 | United States | |
112 | NCT02710110 | April 2016 | 25 February 2019 | Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS) | The Impact of Respiratory Strength Training in Individuals With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Device: PowerLung trainer;Device: Micro Mouth Pressure Meter;Procedure: Pulmonary Function Testing;Procedure: Videofluoroscopic swallowing study;Other: Swallowing Quality of Life Questionnaire;Device: Iowa Oral Pressure Instrument;Drug: Capsaicin | University of Florida | ALS Association | Not recruiting | 21 Years | 85 Years | All | 54 | Early Phase 1 | United States |
113 | NCT02710162 | April 2016 | 8 January 2018 | Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS) | Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Device: Micro Mouth Pressure Meter;Device: Iowa Oral Performance Instrument;Device: Electrical Impedance Myography;Drug: Capsaicin;Procedure: Videofluoroscopic Swallowing Study;Procedure: Pulmonary Function Testing;Other: Swallowing Related Quality of Life Questionnaire;Other: Functional Oral Intake Scale;Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised;Other: Eating Assessment Tool-10;Other: Communicative Effectiveness Survey;Other: The Center for Neurologic Studies Bulbar Function Scale | University of Florida | Not recruiting | 21 Years | 85 Years | All | 21 | Early Phase 1 | United States | |
114 | NCT02714036 | March 2016 | 4 November 2019 | A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) | A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: ibudilast | MediciNova | Massachusetts General Hospital;South Shore Neurologic Associates | Not recruiting | 18 Years | N/A | All | 35 | Phase 1/Phase 2 | United States |
115 | EUCTR2014-005367-32-IT | 29/02/2016 | 3 April 2017 | Clinical study on the efficacy and tolerabilty of Guabenz in Amiotropic Lateral Sclerosis | PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN - PROMISE | Amiotrophic Lateral Sclerosis MedDRA version: 19.1 Level: PT Classification code 10028003 Term: Motor neurone disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: GUANABENZ ACETATO Product Code: GUANA2015 Pharmaceutical Form: Tablet INN or Proposed INN: GUANABENZ CAS Number: 23256-50-0 Current Sponsor code: GUANA2015 Other descriptive name: GUANABENZ Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Product Name: RILUZOLO Pharmaceutical Form: Tablet INN or Proposed INN: RILUZOLO CAS Number: 1744-22-5 Current Sponsor code: RILU2015 Other descriptive name: RILUZOLO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | Authorised | Female: yes Male: yes | 208 | Phase 2 | Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
116 | NCT02623699 | January 20, 2016 | 11 November 2019 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation | Amyotrophic Lateral Sclerosis | Drug: BIIB067;Other: Placebo | Biogen | Ionis Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | All | 144 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Japan;United Kingdom;Italy;Sweden |
117 | ChiCTR-IPR-15007365 | 2015-11-04 | 18 April 2017 | A Multi-center, Randomized, Double Blinding, Placebo-Controlled Clinical Trial of Dl-3-Butylphthalide in the Treatment of Amyotrophic Lateral Sclerosis | A Multi-center, Randomized, Double Blinding, Placebo-Controlled Clinical Trial of Dl-3-Butylphthalide in the Treatment of Amyotrophic Lateral Sclerosis | amyotrophic lateral sclerosis | Treatment group:to give Butylphthalide soft capsules, 2 / time, 3 times / day, fasting;Control group:to give placebo, 2 / time, 3 times / day, fasting; | Peking Union Medical College Hospital | Recruiting | Both | Treatment group:147;Control group:147; | Post-market | China | |||
118 | NCT02460679 | November 2015 | 3 September 2018 | Safety and Biomarker Study of EPI-589 in Subjects With ALS | A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: EPI-589 | Edison Pharmaceuticals Inc | Not recruiting | 21 Years | 70 Years | All | 20 | Phase 2 | United States | |
119 | NCT02469896 | November 2015 | 20 August 2018 | A Trial of Tocilizumab in ALS Subjects | A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects | ALS;Amyotrophic Lateral Sclerosis;Lou Gehrig's Disease;Motor Neuron Disease | Drug: Tocilizumab;Other: Placebo | Barrow Neurological Institute | ALS Association;Barrow Neurological Foundation;Massachusetts General Hospital;Genentech, Inc. | Not recruiting | 18 Years | 75 Years | All | 22 | Phase 2 | United States |
120 | NCT02559869 | November 2015 | 11 June 2018 | Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis | Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | Drug: [18F] GE-180 | Massachusetts General Hospital | The Methodist Hospital System;Cedars-Sinai Medical Center;ALS Association | Recruiting | 18 Years | 80 Years | All | 200 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
121 | NCT02881476 | November 2015 | 5 September 2016 | Therapeutic Treatment of Amyotrophic Lateral Sclerosis | Application of Wharton's Jelly-derived Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Other: Biological: Cell-based therapy | University of Warmia and Mazury | Recruiting | 18 Years | 65 Years | Both | 30 | Phase 1 | ||
122 | NCT02881489 | November 2015 | 5 September 2016 | Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis | Evaluation of Mesenchymal Stem Cell Culturing Protocols in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Other: Biological: Cell-based therapy | University of Warmia and Mazury | Recruiting | 18 Years | 65 Years | Both | 30 | Phase 1 | ||
123 | NCT03296501 | October 13, 2015 | 16 December 2017 | Intraspinal Transplantation of Autologous ADRC in ALS Patients | Safety and Efficacy of Intraspinal Transplantation of Autologous ADRC in ALS Patients | Amyotrophic Lateral Sclerosis | Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients | Mossakowski Medical Research Centre Polish Academy of Sciences | Medical University of Warsaw | Recruiting | 18 Years | 65 Years | All | 30 | Phase 1 | Poland |
124 | JPRN-UMIN000019111 | 2015/10/01 | 2 April 2019 | CaHMB L-arginine-glutamine blended drinks (Abound (TM)) for amyotrophic lateral sclerosis patients and sarcopenia improvement effect by drinking. | Amyotrophic lateral sclerosis | Abound(TM) 1,Take one pack twice a day in the moring and evening 2,Drinking was dissolved in water 240 ~ 300ml 3,Before meals, after meals does not matter 4,12 weeks | National Hospital Organization Takasaki General Medical Center | Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan | ||
125 | NCT02525471 | October 2015 | 5 March 2018 | A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) | ALS | Drug: RNS60 | Sabrina Paganoni, M.D. | Not recruiting | 18 Years | 80 Years | All | 24 | Phase 1 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
126 | NCT02496767 | September 3, 2015 | 20 August 2018 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year | A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: tirasemtiv;Drug: Placebo tablets;Drug: Riluzole 50 MG | Cytokinetics | Not recruiting | 18 Years | N/A | All | 743 | Phase 3 | United States;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom | |
127 | NCT02059759 | September 2015 | 13 June 2016 | Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 | Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 | Amyotrophic Lateral Sclerosis | Drug: Placebo;Drug: 1.0 MIU IL-2 per day;Drug: 2.0 MIU IL-2 per day | Centre Hospitalier Universitaire de Nimes | Not recruiting | 18 Years | 75 Years | Both | 36 | Phase 2 | France | |
128 | EUCTR2015-001431-20-NL | 17/08/2015 | 8 May 2017 | Trial to look at the nerve conductance in patients with ALS, with and without Riluzole or Retigabine. | A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor nerve excitability measurements in patients with ALS. - Peripheral motor nerve excitability study in patients with ALS | Amytrophic Lateral Sclerosis MedDRA version: 18.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rilutek 50 mg film-coated tablets Product Name: Rilutek Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RILUZOLE CAS Number: 1744-22-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Trobalt Product Name: Trobalt Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RETIGABINE CAS Number: 150812-12-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Centre for Human Drug Research | Not Recruiting | Female: yes Male: yes | Phase 2 | Netherlands | ||||
129 | NCT02851914 | July 21, 2015 | 21 January 2019 | SSRIs vs. TCAs for Depression in ALS Patients | An Open-Label Pilot Study Comparing the Efficacy of Selective Serotonin Re-Uptake Inhibitors (SSRIs) Versus Tricyclic Antidepressants (TCAs) for Treating Depression in Amyotrophic Lateral Sclerosis | Depression;Amyotrophic Lateral Sclerosis | Drug: Tricyclic Antidepressants (TCA);Drug: Selective Serotonin Uptake Inhibitors (SSRI) | St. Louis University | Recruiting | 25 Years | 80 Years | All | 40 | Early Phase 1 | United States | |
130 | NCT02487407 | July 2015 | 16 December 2017 | Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis | Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension | Amyotrophic Lateral Sclerosis | Drug: ODM-109;Drug: Placebo for ODM-109 | Orion Corporation, Orion Pharma | Not recruiting | 18 Years | N/A | All | 66 | Phase 2 | Germany;Ireland;Netherlands;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
131 | EUCTR2014-004567-21-IE | 05/06/2015 | 21 August 2017 | Effects of ODM-109 on respiratory function in patients with ALS. | Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension - LEVALS | Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss of respiratory function. The latter is due to the weakness and loss of the diaphragm muscle strength. MedDRA version: 19.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ODM-109 capsule 1 mg Pharmaceutical Form: Capsule INN or Proposed INN: LEVOSIMENDAN CAS Number: 141505-33-1 Current Sponsor code: ODM-109 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Orion Corporation Orion Pharma | Not Recruiting | Female: yes Male: yes | 70 | Phase 2 | Ireland;Netherlands;Germany;United Kingdom | |||
132 | NCT02450552 | June 2015 | 1 October 2018 | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Ezogabine;Drug: Placebo | Brian Wainger | ALS Association;GlaxoSmithKline;Harvard University;Massachusetts General Hospital | Not recruiting | 18 Years | 80 Years | All | 65 | Phase 2 | United States |
133 | NCT02116634 | May 2015 | 25 January 2016 | Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis | Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients | Amyotrophic Lateral Sclerosis | Biological: mesenchymal stem cell | Alzahra Hospital, Iran | Not recruiting | 18 Years | 60 Years | Both | 0 | Phase 1/Phase 2 | Iran, Islamic Republic of | |
134 | NCT02987413 | April 28, 2015 | 16 December 2017 | Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients | Safety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I Trial | Motor Neuron Disease | Biological: Autologous Mesenchymal stem cells (MSCs) | Hospital e Maternidade Dr. Christóvão da Gama | IEP São Lucas - Instituto de Ensino e Pesquisa;Clinica Jordy Sinapse;TECHLIFE - Centro de Tecnologia Celular | Not recruiting | 18 Years | N/A | All | 3 | Phase 1 | Brazil |
135 | NCT02437110 | April 23, 2015 | 4 November 2019 | HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Darunavir;Drug: Ritonavir;Drug: dolutegravir;Drug: Tenofovir alafenamide (TAF) | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 18 Years | N/A | All | 200 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
136 | NCT02463825 | April 2015 | 7 November 2016 | A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS | A Registry-Based Randomized-Controlled, Double-Blinded Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | Drug: Pimozide 2 mg per day;Drug: Pimozide 4 mg per day;Drug: Placebo (Lactose tablet) | University of Calgary | Hotchkiss Brain Institute, University of Calgary | Not recruiting | 18 Years | N/A | Both | 25 | Phase 2 | Canada |
137 | NCT02405403 | March 2015 | 16 December 2017 | Microglial Activation Role In ALS (MARIA) | Microglial Activation Role In ALS (MARIA) | Amyotrophic Lateral Sclerosis | Drug: [18F]DPA-714 PET | University Hospital, Tours | Not recruiting | 18 Years | N/A | All | 0 | Early Phase 1 | France | |
138 | JPRN-UMIN000016352 | 2015/02/01 | 2 April 2019 | The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis: Single centered open label trial | amyotrophic lateral sclerosis | edaravone | Ehime University Hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 10 | Phase 1,2 | Japan | ||
139 | NCT02306590 | February 2015 | 11 March 2019 | Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Dietary Supplement: Calogen;Dietary Supplement: Placebo | University of Ulm | Not recruiting | 18 Years | N/A | All | 207 | N/A | Germany | ||
140 | NCT02414230 | February 2015 | 4 February 2019 | F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis | F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Drug: F 18 T807 | Washington University School of Medicine | Not recruiting | 18 Years | N/A | All | 9 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
141 | NCT02269436 | January 2015 | 8 February 2016 | A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS | A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: sNN0029 infusion solution | Newron Sweden AB | Not recruiting | 18 Years | 75 Years | Both | 11 | Phase 1 | Belgium;Netherlands | |
142 | NCT02288091 | January 2015 | 16 December 2017 | A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) | A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Inosine | Massachusetts General Hospital | The Salah Foundation;MGH cure ALS Fund | Not recruiting | 18 Years | N/A | All | 32 | Phase 1 | United States |
143 | ChiCTR-IOR-14005674 | 2014-12-30 | 18 April 2017 | Open randomized controlled trial of the Jianpi Yifei Decoction in the treatment of bulbar paralysis of amyotrophic lateral sclerosis | Open randomized controlled trial of the Jianpi Yifei Decoction in the treatment of bulbar paralysis of amyotrophic lateral sclerosis | amyotrophic lateral sclerosis | Chinese medicine :Jianpi Yifei Decoction ;Riluzole:Riluzole; | Guangdong Province Traditional Chinese Medical Hospital | Not Recruiting | 18 | 80 | Both | Chinese medicine :30;Riluzole:30; | Other | China | |
144 | NCT02479802 | November 2014 | 26 February 2018 | Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis | Pilot Study on the Effects of Plasma Exchange on Motor Dysfunction and Cognitive Function in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: Albumin | Instituto Grifols, S.A. | Not recruiting | 18 Years | 70 Years | All | 13 | Phase 2 | Spain | |
145 | JPRN-UMIN000015054 | 2014/09/21 | 2 April 2019 | An investigator initiated clinical trial in healthy adults to evaluate safety and pharmacokinetics of WN1316, a candidate drug of amyotrophic lateral sclerosis | Amyotrophic Lateral Sclerosis (ALS) | WN1316 solution 5mL is administered single dose orally. The dosage of WN1316 is 60 micrograms in step 1, 180 micrograms in step 2, 600 micrograms in step 3. Placebo (Distilled water) 5 mL is administered single dose orally. | Clinical Research Hospital Tokyo | Not Recruiting | 20years-old | 35years-old | Male | 24 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
146 | EUCTR2012-002099-15-SE | 15/09/2014 | 12 September 2016 | Safety and Efficacy of Apovir for treatment of patients with ALS (Amyotrophic lateral sclerosis) | A randomised, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Amyotrophic lateral sclerosis | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 17.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pleconaril Product Code: APO-P001 Pharmaceutical Form: Capsule, hard INN or Proposed INN: PLECONARIL CAS Number: 153168-05-9 Current Sponsor code: APO-P001 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Copegus Product Name: Ribavirin Pharmaceutical Form: Capsule, hard CAS Number: 36791-04-5 Other descriptive name: RIBAVIRIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Apodemus AB | Not Recruiting | Female: yes Male: yes | Phase 2 | Sweden | ||||
147 | EUCTR2014-002228-28-IT | 01/09/2014 | 7 October 2014 | STEMALS-II | A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis - STEMALS-II | Amyotrophic lateral sclerosis (ALS) is a severe progressive neurological disorder characterized by a selective degeneration of spinal, bulbar, and cortical motor neurons.;Therapeutic area: Not possible to specify | Trade Name: TEVAGRASTIM Product Name: filgrastim Pharmaceutical Form: Injection Pharmaceutical form of the placebo: Injection Route of administration of the placebo: Intravenous use Trade Name: MANNITOLO 18% LDB Product Name: MANNITOLO 18% Pharmaceutical Form: Injection Trade Name: PERFALGAN Product Name: PARACETAMOLO Pharmaceutical Form: Injection | Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino | Authorised | Female: yes Male: yes | 90 | Italy | ||||
148 | NCT01999803 | September 2014 | 8 February 2016 | A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS | A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion Solution | Amyotrophic Lateral Sclerosis | Drug: sNN0029;Drug: Placebo | Newron Sweden AB | Not recruiting | 18 Years | 75 Years | Both | 15 | Phase 1 | Belgium;Netherlands | |
149 | NCT02238626 | September 2014 | 10 December 2018 | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS) | Amyotrophic Lateral Sclerosis | Drug: Placebo (for MN-166);Drug: MN-166;Drug: riluzole | MediciNova | Carolinas Healthcare System | Not recruiting | 18 Years | 80 Years | All | 71 | Phase 2 | United States |
150 | NCT02492516 | September 2014 | 16 December 2017 | Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS | Evaluation the Safety of Intravenous Injection of Adipose Derived Mesenchymal Stem Cell in Patients With ALS | Amyotrophic Lateral Sclerosis | Biological: mesenchymal stem cells | Royan Institute | Not recruiting | 18 Years | 55 Years | All | 19 | Phase 1 | Iran, Islamic Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
151 | NCT02236065 | August 2014 | 16 December 2017 | Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders | A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders | Brain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's Disease | Procedure: Umbilical cord blood therapy;Biological: Filgrastim | MinYoung Kim, M.D. | Not recruiting | 19 Years | 75 Years | All | 10 | N/A | Korea, Republic of | |
152 | EUCTR2011-004801-25-ES | 16/07/2014 | 5 August 2014 | CLINICAL TRIAL ON THE USE OF BONE MARROW OWN PATIENT'S WITH AMYOTROPHIC LATERAL SCLEROSIS | A PHASE I/II CLINICAL TRIAL OF THE BONE MARROW'S AUTOLOGOUS STEM CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS | amyotrophic lateral sclerosis MedDRA version: 15.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: células troncales hematopoyéticas autólogas adultas extraidas de médula ósea Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: autologous bone marrow mononucleated cells CAS Number: no available Current Sponsor code: TCIM/ELA Other descriptive name: autologous bone marrow mononucleated cells Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intramuscular use | Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO) | Authorised | Female: yes Male: yes | Phase 1/2 | Spain | ||||
153 | NCT02152449 | July 2014 | 15 July 2019 | Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients | Impact on Functional Status of Early Oral Nutritional Supplementation (ONS) in Amyotrophic Lateral Sclerosis (ALS) Patients | Amyotrophic Lateral Sclerosis (ALS) | Dietary Supplement: Oral nutritional supplementation | University Hospital, Limoges | Laboratoires NUTRICIA | Not recruiting | 18 Years | N/A | All | 229 | N/A | France |
154 | NCT02290886 | July 2014 | 9 September 2019 | A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral | A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe | Amyotrophic Lateral Sclerosis | Other: Intravenous administration of placebo;Drug: Intravenous administration of 1 million of MSC;Drug: Intravenous administration of 2 million of MSC;Drug: Intravenous administration of 4 million of MSC | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Iniciativa Andaluza en Terapias Avanzadas | Not recruiting | 18 Years | N/A | All | 52 | Phase 1/Phase 2 | Spain |
155 | NCT03367650 | May 13, 2014 | 16 December 2017 | Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies | Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies | Amyotrophic Lateral Sclerosis | Dietary Supplement: Blood sample and environmental survey | Centre Hospitalier Universitaire de Pointe-a-Pitre | Recruiting | 18 Years | N/A | All | 70 | N/A | Guadeloupe;Martinique | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
156 | EUCTR2013-004842-40-ES | 09/05/2014 | 4 July 2016 | Pilot study to evaluate the effect of plasma exchange with albumin in patients with amyotrophic lateral sclerosis | Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis - Albumin in ALS | Amytrophic Lateral Sclerosis (ALS) MedDRA version: 16.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Albutein 5% Pharmaceutical Form: Solution for infusion INN or Proposed INN: albúmina humana Other descriptive name: HUMAN ALBUMIN SOLUTION Concentration unit: g/l gram(s)/litre Concentration type: equal Concentration number: 50- | Instituto Grifols S.A. | Not Recruiting | Female: yes Male: yes | Phase 4 | Spain | ||||
157 | NCT02017912 | May 2014 | 30 July 2018 | Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS | Amyotrophic Lateral Sclerosis (ALS) | Biological: Autologous MSC-NTF cells;Biological: Placebo | Brainstorm-Cell Therapeutics | Not recruiting | 18 Years | 75 Years | All | 48 | Phase 2 | United States | |
158 | NCT02166944 | April 2014 | 30 September 2019 | Tamoxifen Treatment in Patients With Motor Neuron Disease | The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease | Amyotrophic Lateral Sclerosis;ALS Functional Ration Scale;TAR-DNA-binding Protein-43;Tamoxifen;mTOR | Drug: tamoxifen 40 mg daily for one year | Taipei Medical University Shuang Ho Hospital | Not recruiting | 20 Years | 80 Years | All | 20 | Phase 1/Phase 2 | Taiwan | |
159 | NCT01759784 | March 2014 | 18 January 2016 | Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS | Safety of Intraventricular Injection of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS | Amyotrophic Lateral Sclerosis | Biological: Intraventricular injection | Royan Institute | Not recruiting | 18 Years | 70 Years | Both | 0 | Phase 1 | Iran, Islamic Republic of | |
160 | NCT02039401 | February 2014 | 28 October 2019 | Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis | A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: VM202 | Helixmith Co., Ltd. | Not recruiting | 21 Years | 75 Years | All | 18 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
161 | NCT02645461 | January 2014 | 18 January 2016 | Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS | Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS | Amyotrophic Lateral Sclerosis | Drug: endocannabinoid palmitoylethanolamide (PEA);Drug: Riluzole | University of Roma La Sapienza | Not recruiting | 18 Years | N/A | Both | 50 | N/A | ||
162 | NCT01884571 | October 2013 | 16 December 2017 | Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) | A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Basiliximab;Drug: Methylprednisolone;Drug: Prednisone;Drug: Tacrolimus;Drug: Mycophenolate mofetil | Emory University | ALS Association | Not recruiting | 18 Years | N/A | All | 31 | Phase 2 | United States |
163 | JPRN-UMIN000011494 | 2013/09/02 | 2 April 2019 | Assessment of the efficacy and the influence on swallowing function of transdermal scopolamine for ALS patinets' drooling | amyotrophic lateral sclerosis | scopolamine patch 7days-washout 7days-placebo patch 7days placebo patch 7days-washout 7days-scopolamine patch 7days | Mie University Graduate school of medicine,Department of neurology | Matsusaka Chuou Hospital National Mie Hospital | Not Recruiting | Not applicable | Not applicable | Male and Female | 10 | Not applicable | Japan | |
164 | NCT01935518 | September 2013 | 19 February 2015 | A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Historical Placebo Controlled Screening Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Fasudil | Peking University Third Hospital | Recruiting | 18 Years | 70 Years | Both | 10 | Phase 2 | China | |
165 | NCT02164253 | September 2013 | 16 December 2017 | Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients | Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis);Iron Overload | Drug: Deferiprone | University Hospital, Lille | ApoPharma | Not recruiting | 18 Years | 85 Years | All | 23 | Phase 2 | France |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
166 | NCT01771640 | August 2013 | 11 June 2018 | Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS | Intrathecal Transplantation of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS | Amyotrophic Lateral Sclerosis | Biological: intrathecal injection | Royan Institute | Not recruiting | 18 Years | 65 Years | All | 8 | Phase 1 | Iran, Islamic Republic of | |
167 | NCT01786174 | August 2013 | 19 October 2017 | Gilenya in Amyotrophic Lateral Sclerosis (ALS) | Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Gilenya;Other: Placebo | Massachusetts General Hospital | ALS Therapy Development Institute | Not recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
168 | NCT01854294 | August 2013 | 26 August 2019 | GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) | GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) | Amyotrophic Lateral Sclerosis | Drug: GM604;Drug: Placebo comparator | Genervon Biopharmaceuticals, LLC | Columbia University;Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States |
169 | NCT01849770 | July 2013 | 19 October 2017 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS) | A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS) | Sporadic Amyotrophic Lateral Sclerosis | Drug: Mexiletine;Drug: Placebo | University of Washington | Not recruiting | 18 Years | N/A | All | 75 | Phase 2 | United States | |
170 | NCT01906658 | July 2013 | 19 October 2017 | A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis | A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Repository corticotropin injection | Mallinckrodt | Not recruiting | 18 Years | 80 Years | All | 43 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
171 | NCT01811355 | May 2013 | 16 December 2017 | Mexiletine for the Treatment of Muscle Cramps in ALS | Mexiletine for the Treatment of Muscle Cramps in ALS | Muscle Cramps in Amyotrophic Lateral Sclerosis | Drug: Mexiletine;Drug: Placebo | Bjorn Oskarsson, MD | University of California, Davis;ALS Association | Not recruiting | 21 Years | 89 Years | All | 23 | Phase 4 | United States |
172 | EUCTR2011-004482-32-DE | 10/04/2013 | 8 August 2016 | Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) | Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - RAS-ALS Trial | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: AZILECT® 1 mg Tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline Mesilate CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESILATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Universitätsklinikum Ulm | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | ||||
173 | NCT01806857 | April 2013 | 16 December 2017 | Clinical Trial Nuedexta in Subjects With ALS | The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Nuedexta;Drug: Matching Placebo | Center for Neurologic Study, La Jolla, California, | ALS Association;State University of New York - Upstate Medical University | Not recruiting | 18 Years | N/A | All | 90 | Phase 2 | United States |
174 | NCT02588677 | April 2013 | 18 December 2018 | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) | Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib | Amyotrophic Lateral Sclerosis (ALS) | Drug: Masitinib (4.5);Drug: Riluzole;Drug: Placebo;Drug: Masitinib (3.0) | AB Science | Not recruiting | 18 Years | N/A | All | 394 | Phase 2/Phase 3 | Spain | |
175 | EUCTR2011-004798-99-DE | 27/02/2013 | 27 October 2014 | Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) | Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) - Pyrimethamine In Familial ALS | Familial amyotrophic lateral sclerosis (FALS) MedDRA version: 14.1 Level: LLT Classification code 10036704 Term: Primary lateral sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Daraprim Pharmaceutical Form: Tablet INN or Proposed INN: PYRIMETHAMINE CAS Number: 58-14-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Weill Medical College of Cornell University | Not Recruiting | Female: yes Male: yes | 40 | United States;Germany;Italy | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
176 | EUCTR2011-006254-85-ES | 08/02/2013 | 25 February 2013 | Clinical trial to value the safety and efficacy of administration of stem cells derived from own patient for the treatment of Amyotrophic Lateral Sclerosis (ALS). | Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three doses of autologous adipose derived autologous mesenchymal stem cells (CeTMAd) in moderate/severe ALS patients. | Amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Células madre mesenquimales de tejido adiposo autólogo Pharmaceutical Form: Suspension for infusion INN or Proposed INN: NA CAS Number: NA Current Sponsor code: NA Other descriptive name: Células Mesenquimales de tejido adiposo Concentration unit: kg kilogram(s) Concentration type: range Concentration number: 4000000-1000000 Pharmaceutical form of the placebo: Suspension for infusion Route of administration of the placebo: Intravenous use | FUNDACIÓN PROGRESO Y SALUD | Authorised | Female: yes Male: yes | Phase 1/2 | Spain | ||||
177 | EUCTR2010-024423-24-ES | 29/01/2013 | 30 April 2018 | Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) | A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable | patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Masitinib mesylate CAS Number: 790299-79-5 Current Sponsor code: AB1010 Other descriptive name: MASITINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | ABScience | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | Portugal;France;Hungary;Slovakia;Greece;Spain;Ireland;Netherlands;Italy | |||
178 | NCT01759797 | January 2013 | 21 July 2016 | Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS | Safety of Intravenous Transplantation of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS | Amyotrophic Lateral Sclerosis | Biological: intra venous injection of stem cell | Royan Institute | Not recruiting | 18 Years | 65 Years | Both | 6 | Phase 1 | Iran, Islamic Republic of | |
179 | NCT01776970 | January 2013 | 16 December 2017 | Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease | A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients | Motor Neuron Disease;Amyotrophic Lateral Sclerosis (ALS) | Drug: Cannabis Sativa extract Oromucosal spray | Ospedale San Raffaele | Fondazione Salvatore Maugeri;Niguarda Hospital;University of Padova | Not recruiting | 18 Years | 80 Years | All | 60 | Phase 2/Phase 3 | Italy |
180 | NCT01835782 | January 2013 | 10 August 2015 | Determining the Safety of L-serine in ALS | Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses. | Amyotrophic Lateral Sclerosis (ALS) | Drug: L-Serine | Phoenix Neurological Associates, LTD | Institute for Ethnomedicine | Not recruiting | 18 Years | 85 Years | Both | 20 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
181 | EUCTR2012-003349-13-BE | 06/12/2012 | 17 August 2015 | A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 15.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Ozanezumab CAS Number: 1310680-64-8 Current Sponsor code: GSK1223249 Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | GlaxoSmithKline Research and Development Limited | Not Recruiting | Female: yes Male: yes | 294 | Phase 2 | Australia;Germany;Netherlands;United Kingdom;France;United States;Canada;Belgium;Italy;Japan;Korea, Republic of | |||
182 | NCT01753076 | December 1, 2012 | 16 December 2017 | Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis | Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Ozanezumab;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 80 Years | All | 304 | Phase 2 | United States;Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom | |
183 | NCT01777646 | December 2012 | 11 June 2018 | Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS). | Amyotrophic Lateral Sclerosis | Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Brainstorm-Cell Therapeutics | Hadassah Medical Organization | Not recruiting | 20 Years | 75 Years | All | 14 | Phase 2 | Israel |
184 | NCT01825551 | November 2012 | 19 February 2015 | The Effect of GCSF in the Treatment of ALS Patients | The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013 | Amyotrophic Lateral Sclerosis | Drug: Granulocyte Colony Stimulating Factor;Drug: Placebo | Tehran University of Medical Sciences | Not recruiting | 18 Years | 85 Years | Both | 40 | Phase 2/Phase 3 | Iran, Islamic Republic of | |
185 | NCT01160263 | October 2012 | 25 May 2015 | Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls | Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT | Amyotrophic Lateral Sclerosis | Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM | Assistance Publique - Hôpitaux de Paris | Association Française contre les Myopathies (AFM), Paris;ARS (Association pour la Recherche sur la Sclérose Latérale Amyotrophique);AGEPS | Not recruiting | 39 Years | 66 Years | Both | 16 | Phase 3 | France |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
186 | NCT01709149 | October 2012 | 16 December 2017 | Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) | A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS) | Amyotrophic Lateral Sclerosis | Drug: CK-2017357;Other: Placebo tablets;Drug: Riluzole | Cytokinetics | Not recruiting | 18 Years | N/A | All | 711 | Phase 2 | United States;Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom | |
187 | NCT01786603 | September 2012 | 16 December 2017 | Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | Drug: Rasagiline;Drug: Placebo | Richard Barohn, MD | Not recruiting | 21 Years | 80 Years | All | 80 | Phase 2 | United States | |
188 | NCT01933321 | September 2012 | 13 April 2015 | Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) | Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Biological: Intrathecal autologous stem cell | Hospital Universitario Dr. Jose E. Gonzalez | Not recruiting | 18 Years | N/A | Both | 14 | Phase 2/Phase 3 | Mexico | |
189 | EUCTR2011-006119-70-SE | 15/05/2012 | 3 June 2013 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Pharmaceutical Form: Film-coated tablet CAS Number: 908244-04-2 Current Sponsor code: BIIB050 / KNS-760704 Other descriptive name: Dexpramipexole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | ||||
190 | NCT01609283 | May 2012 | 16 September 2019 | A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis | A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: autologous mesenchymal stem cells | Mayo Clinic | Not recruiting | 18 Years | N/A | All | 27 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
191 | EUCTR2011-000362-35-CZ | 29/03/2012 | 4 September 2017 | Safety and Efficacy of Stem Cell Therapy of Motor Neuron Disease. | A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. - AMSC in ALS | Amyotrophic lateral sclerosis MedDRA version: 17.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Suspension of human autologous MSC 3P in 1,5 ml Product Code: AMSC Pharmaceutical Form: Suspension for injection INN or Proposed INN: Human autologous mesenchymal stem cells Current Sponsor code: AMSC Concentration unit: million organisms/ml million organisms/millilitre Concentration type: range Concentration number: 7-13 | Bioinova, s.r.o. | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Czech Republic | |||
192 | NCT01536249 | March 2012 | 19 February 2015 | Dexpramipexole and Cimetidine Drug Drug Interaction (DDI) | An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers | Amyotrophic Lateral Sclerosis | Drug: Dexpramipexole;Drug: Cimetidine plus Dexpramipexole | Knopp Biosciences | Not recruiting | 18 Years | 55 Years | Both | 14 | Phase 1 | United States | |
193 | NCT01565395 | March 2012 | 16 December 2017 | Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | Parkinson Disease;Amyotrophic Lateral Sclerosis | Drug: Incobotulinum Toxin A;Drug: placebo | Beth Israel Deaconess Medical Center | Merz Pharmaceuticals | Not recruiting | 20 Years | 80 Years | All | 0 | Phase 2 | United States |
194 | NCT01551940 | February 2012 | 24 August 2015 | Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea | Evaluation of Efficacy of Botulinum Toxin Type A in the Treatment of Sialorrhea in the Patient Affected by Amyotrophic Lateral Sclerosis (ALS) | Sialorrhea;Amyotrophic Lateral Sclerosis | Drug: Botox injection;Drug: Placebo injection | Hospices Civils de Lyon | Not recruiting | 18 Years | N/A | Both | 18 | Phase 2 | France | |
195 | NCT01511029 | January 2012 | 19 February 2015 | Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate) | A Single-Center, Randomized, Blinded, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Dexpramipexole (BIIB050) on the QTc Interval in Healthy Volunteers | Amyotrophic Lateral Sclerosis | Drug: Dexpramipexole;Drug: Dexpramipexole Placebo;Drug: Moxifloxacin | Knopp Biosciences | Not recruiting | 18 Years | 60 Years | Both | 68 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
196 | NCT03828123 | January 2012 | 25 February 2019 | Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis | A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Biological: Suspension of human autologous MSC 3P in 1.5 ml | Bioinova, s.r.o. | Department of Neurology, University Hospital Motol, Prague, Czech Republic | Not recruiting | 18 Years | 65 Years | All | 26 | Phase 1/Phase 2 | |
197 | NCT01232738 | December 2011 | 11 June 2018 | Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: rasagiline | Yunxia Wang, MD | Western ALS Study Group | Not recruiting | 21 Years | 80 Years | All | 36 | Phase 2 | United States;Canada |
198 | NCT01492686 | December 2011 | 29 June 2015 | Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis | Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2 | Amyotrophic Lateral Sclerosis (ALS) | Drug: MCI-186;Drug: Placebo;Drug: MCI-186 in open label phase | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 20 Years | 75 Years | Both | 137 | Phase 3 | Japan | |
199 | NCT01640067 | December 2011 | 18 January 2016 | Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS) | Intra-spinal Cord Delivery of Human Neural Stem Cells in ALS Patients: Proposal for a Phase I Study/ Trapianto Intramidollare di Cellule Staminali Neurali Umane Come Terapia Putativa Per la SLA: Proposta di un Trial Clinico di Fase I | Amyotrophic Lateral Sclerosis | Biological: Human Neural Stem Cells | Azienda Ospedaliera Santa Maria, Terni, Italy | Azienda Ospedaliero Universitaria Maggiore della Carita;Università di Padova Italy | Not recruiting | 20 Years | 75 Years | Both | 18 | Phase 1 | Italy |
200 | EUCTR2010-023161-21-FR | 23/11/2011 | 3 April 2017 | Sclérose Latérale Amyotrophique (SLA) – toxine botulinique A (Botox®) | Evaluation de la toxine botulinique dans le traitement du trouble salivaire chez le patient atteint de sclérose latérale amyotrophique - SLA-TOX | Sclérose Latérale Amyotrophique (SLA) MedDRA version: 14.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: BOTOX 100 UNITES ALLERGAN (PR1) Pharmaceutical Form: Powder for solution for injection CAS Number: 93384-43-1 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Other use (Noncurrent) | Hospices Civils de Lyon | Authorised | Female: yes Male: yes | Phase 2 | France | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
201 | NCT01449578 | November 2011 | 19 February 2015 | Dexpramipexole SAD/MAD Study | A Randomized, Blinded, Placebo-Controlled Ascending Dose Study of the Safety and Pharmacokinetics of Dexpramipexole in Healthy Volunteers | Amyotrophic Lateral Sclerosis | Drug: Dexpramipexole;Drug: Dexpramipexole Placebo | Knopp Biosciences | Not recruiting | 18 Years | 55 Years | Both | 63 | Phase 1 | United States | |
202 | NCT01486849 | November 2011 | 13 May 2019 | Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: CK-2017357;Drug: Placebo;Drug: Riluzole 50 MG | Cytokinetics | Not recruiting | 18 Years | N/A | All | 27 | Phase 2 | United States | |
203 | JPRN-UMIN000006423 | 2011/10/01 | 2 April 2019 | The clinical trial to assess efficacy of mexiletine for amyotrophic lateral sclerosis | amyotrophic lateral sclerosis | administration of mexiletine and riluzole administration of riluzole only | Department of Neurology, Graduate School of Medicine, Chiba University, Japan. | Not Recruiting | 20years-old | Not applicable | Male and Female | 60 | Not selected | Japan | ||
204 | EUCTR2011-001329-26-IT | 03/08/2011 | 3 February 2014 | Erythropoietin in Amyotrophic Lateral Sclerosis: a study to identify the best dose and the optimal route of administration and evaluate the safety | ErythroPOietin in ALS: a Study of dose-finding and Safety - EPOSS2010 | Amyotrophic Lateral Sclerosis MedDRA version: 14.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: EPREX*1SIR 40000UI/ML 1ML Pharmaceutical Form: Solution for injection INN or Proposed INN: ERYTHROPOIETIN CAS Number: 11096-26-7 Concentration unit: U/ml unit(s)/millilitre Concentration type: equal Concentration number: 40000- | ISTITUTO NEUROLOGICO CARLO BESTA | Authorised | Female: yes Male: yes | 40 | Italy | ||||
205 | NCT01424163 | August 2011 | 19 February 2015 | Dexpramipexole Japanese PK Study | A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects | Amyotrophic Lateral Sclerosis | Drug: Single dose reduced;Drug: Single dose standard;Drug: Multiple Dose | Knopp Biosciences | Biogen Idec | Not recruiting | 18 Years | 60 Years | Both | 56 | Phase 1 | United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
206 | NCT01424176 | July 2011 | 19 February 2015 | Dexpramipexole Renal PK Study | A Multicenter, Open-Label, Single-dose, Pharmacokinetic and Safety Study of Dexpramipexole (BIIB050) in Healthy Subjects and Subjects With Renal Impairment | Amyotrophic Lateral Sclerosis;Renal Insufficiency | Drug: Dexpramipexole (dose 1);Drug: Dexpramipexole (dose 2) | Knopp Biosciences | Not recruiting | 18 Years | 75 Years | Both | 36 | Phase 1 | United States | |
207 | NCT01051882 | June 2011 | 21 January 2019 | Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. | A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. | Amyotrophic Lateral Sclerosis | Biological: MSC-NTF cells transplantation (IM);Biological: MSC-NTF cells transplantation (IT) | Brainstorm-Cell Therapeutics | Hadassah Medical Organization | Not recruiting | 20 Years | 75 Years | All | 12 | Phase 1/Phase 2 | Israel |
208 | NCT01378676 | June 2011 | 13 May 2019 | A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Placebo (Part A);Drug: CK-2017357 (Part A);Drug: Riluzole 50 MG (Part B);Drug: Placebo (Part B);Drug: CK-2017357 (Part B) | Cytokinetics | Not recruiting | 18 Years | N/A | All | 49 | Phase 2 | United States | |
209 | EUCTR2010-022818-19-GB | 22/03/2011 | 4 February 2013 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Dexpramipexole Dichydrochloride CAS Number: 908244-04-2 Current Sponsor code: BIIB050 / KNS-760704 Other descriptive name: Dexpramipexole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Biogen Idec Limited | Not Recruiting | Female: yes Male: yes | 915 | United States;Canada;Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden | ||||
210 | EUCTR2010-021179-10-DE | 15/03/2011 | 22 October 2012 | An Open-Label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. | An Open-Label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. | Amyotrophic Lateral Sclerosis. MedDRA version: 12.1 Level: LLT Classification code 10052889 Term: ALS | Product Name: olesoxime Product Code: TRO19622 Pharmaceutical Form: Capsule, soft INN or Proposed INN: olesoxime CAS Number: 2203-87-0 Current Sponsor code: TRO19622 Other descriptive name: 4-cholesten-3-one, oxime Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 165- | TROPHOS SA | Not Recruiting | Female: yes Male: yes | Spain;Germany;United Kingdom | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
211 | NCT00876772 | March 2011 | 19 February 2015 | Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) | Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Olanzapine | Charite University, Berlin, Germany | Recruiting | 18 Years | 80 Years | Both | 40 | Phase 2/Phase 3 | Germany | |
212 | NCT01257581 | March 2011 | 19 October 2017 | Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: creatine;Drug: tamoxifen | Nazem Atassi | ALS Therapy Alliance;State University of New York - Upstate Medical University | Not recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States |
213 | NCT01277315 | February 2011 | 19 February 2015 | Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis | Open Safety and Tolerability Trial to Evaluate a Subcutaneous Injection Solution of 100 mg of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | Drug: Anakinra | Charite University, Berlin, Germany | Max Planck Institute for Infection Biology | Recruiting | 18 Years | 80 Years | Both | 20 | Phase 2 | Germany |
214 | NCT01281631 | February 2011 | 19 February 2015 | A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: NP001;Drug: Placebo | Neuraltus Pharmaceuticals, Inc. | Not recruiting | 21 Years | 80 Years | Both | 136 | Phase 2 | United States | |
215 | NCT01363401 | February 2011 | 16 December 2017 | Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;ALS | Biological: HYNR-CS inj;Other: Control group | Corestem, Inc. | Not recruiting | 25 Years | 75 Years | All | 72 | Phase 1/Phase 2 | Korea, Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
216 | NCT02880033 | February 2011 | 15 July 2019 | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis | Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload | Drug: deferiprone;Drug: placebo | University Hospital, Lille | Not recruiting | 18 Years | 80 Years | All | 90 | N/A | France | |
217 | EUCTR2010-022808-40-IT | 13/01/2011 | 27 January 2014 | A fase II, randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients - ND | A fase II, randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients - ND | amyotrophic lateral sclerosis MedDRA version: 9.1 Level: PT Classification code 10002026 | Trade Name: sativex Pharmaceutical Form: Oromucosal spray INN or Proposed INN: sativex Concentration unit: µl microlitre(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Buccal use | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | Authorised | Female: yes Male: yes | Italy | |||||
218 | NCT01259050 | October 2010 | 19 February 2015 | Safety Study of High Doses of Zinc in ALS Patients | Phase 1 Open Label Study of Zinc Therapy in ALS Patients | Amyotrophic Lateral Sclerosis | Drug: Zinc and Copper | Phoenix Neurological Associates, LTD | Not recruiting | 18 Years | 85 Years | Both | 10 | Phase 1/Phase 2 | United States | |
219 | NCT01285583 | October 2010 | 5 December 2016 | Safety Extension Study of TRO19622 in ALS | An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole | Amyotrophic Lateral Sclerosis | Drug: TRO19622 | Hoffmann-La Roche | Not recruiting | N/A | N/A | Both | 271 | Phase 2/Phase 3 | Belgium;France;Germany;Spain;United Kingdom | |
220 | NCT03085706 | October 2010 | 19 February 2018 | Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis | Transplantation of Autologous Peripheral Blood Mononuclear Cells in the Subarachnoid Space for Amyotrophic Lateral Sclerosis: a Safety Analysis of 14 Patients | Amyotrophic Lateral Sclerosis | Biological: PBMC autotransplantation | The First Affiliated Hospital of Dalian Medical University | Not recruiting | 31 Years | 75 Years | All | 14 | N/A | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
221 | EUCTR2010-020257-13-IT | 30/07/2010 | 19 March 2012 | A pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis - EPERISONE AND ALS | A pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis - EPERISONE AND ALS | PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS MedDRA version: 9.1 Level: SOC Classification code 10029205 | Trade Name: MYONAL*30CPR RIV 100MG Pharmaceutical Form: Tablet INN or Proposed INN: EPERISONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: LIORESAL*50CPR 10MG Pharmaceutical Form: Tablet INN or Proposed INN: Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | AZIENDA OSPEDALIERO-UNIVERSITARIA | Not Recruiting | Female: yes Male: yes | Phase 2 | Italy | ||||
222 | NCT01091142 | July 2010 | 19 February 2015 | Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS) | Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: NP001;Drug: Placebo | Neuraltus Pharmaceuticals, Inc. | Not recruiting | 21 Years | 75 Years | Both | 56 | Phase 1 | United States | |
223 | EUCTR2008-003982-21-FR | 10/06/2010 | 16 November 2015 | Etude des transporteurs de la dopamine et de la sérotonine en imagerie TEMP utilisant les radiopharmaceutiques 123I-FP-CIT (datscan) and 123 I-ADAM dans la sclérose latérale amyotrophique et dans une population contrôle. DOSERALS - DOSERALS | Etude des transporteurs de la dopamine et de la sérotonine en imagerie TEMP utilisant les radiopharmaceutiques 123I-FP-CIT (datscan) and 123 I-ADAM dans la sclérose latérale amyotrophique et dans une population contrôle. DOSERALS - DOSERALS | Patients présentant une SLA et volontaires sains MedDRA version: 8.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: DaTSCAN Product Name: Datscan Pharmaceutical Form: Solution for injection INN or Proposed INN: Ioflupane 123I Concentration unit: MBq/ml megabecquerel(s)/millilitre Concentration type: equal Concentration number: 74- Product Name: [I-123] ADAM Pharmaceutical Form: Solution for injection INN or Proposed INN: [I-123] ADAM Concentration unit: MBq/ml megabecquerel(s)/millilitre Concentration type: equal Concentration number: 30 +/- 10- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Not Recruiting | Female: yes Male: yes | France | |||||
224 | NCT01142856 | June 2010 | 19 February 2015 | Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS) | A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Biological: autologous mesenchymal stem cells | Mayo Clinic | Not recruiting | 18 Years | N/A | Both | 1 | Phase 1 | United States | |
225 | EUCTR2009-016066-91-IT | 10/03/2010 | 19 March 2012 | SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND | SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND | ALS MedDRA version: 9.1 Level: SOC Classification code 10029205 | Trade Name: EPREX*1SIR 40000UI/ML 1ML Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Erythropoietin Concentration unit: U unit(s) Concentration type: equal Concentration number: 40000- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use | ISTITUTO NEUROLOGICO CARLO BESTA | Authorised | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
226 | NCT01082653 | March 2010 | 19 February 2015 | Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis | Phase I, Single Center, Prospective, Non-randomized, Open Label, Safety/Efficacy Study of the Infusion of Autologous Bone Marrow-derived Stem Cells, in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: autologous bone marrow-derived stem cells | TCA Cellular Therapy | Not recruiting | 18 Years | 80 Years | Both | 6 | Phase 1 | United States | |
227 | NCT01089010 | March 2010 | 20 May 2019 | A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357 | Cytokinetics | Not recruiting | 18 Years | N/A | All | 67 | Phase 2 | United States | |
228 | NCT01041222 | January 2010 | 19 February 2015 | Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations | A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients With Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations | Familial Amyotrophic Lateral Sclerosis | Drug: ISIS 333611 | Isis Pharmaceuticals | Muscular Dystrophy Association;ALS Association | Not recruiting | 18 Years | N/A | Both | 33 | Phase 1 | United States |
229 | NCT02193893 | January 2010 | 19 February 2015 | Biological Treatment of Amyotrophic Lateral Sclerosis | Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells | Amyotrophic Lateral Sclerosis | Other: Biological: Cell-based therapeutics;Other: Symptomatic treatment of ALS | Pomeranian Medical University Szczecin | Recruiting | 18 Years | 65 Years | Both | 50 | Phase 1 | Poland | |
230 | NCT01016522 | November 2009 | 13 April 2015 | Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) | Safety and Tolerability of the Ketogenic Diet in ALS | Amyotrophic Lateral Sclerosis | Dietary Supplement: KetoCal | Johns Hopkins University | Nutricia North America;Cornell University | Not recruiting | 18 Years | N/A | Both | 1 | Phase 3 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
231 | NCT01083667 | November 2009 | 16 December 2017 | SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) | Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS | Familial Amyotrophic Lateral Sclerosis | Drug: Pyrimethamine | Weill Medical College of Cornell University | Muscular Dystrophy Association | Not recruiting | 18 Years | N/A | All | 32 | Phase 1/Phase 2 | United States;Germany;Italy;Sweden |
232 | NCT00983983 | October 2009 | 19 October 2017 | High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis | Phase II Safety and Tolerability Study of High Fat/High Calorie Versus High Calorie Versus Optimal Nutrition in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Dietary Supplement: Oxepa;Dietary Supplement: Jevity 1.5;Dietary Supplement: Jevity 1.0 | Massachusetts General Hospital | Muscular Dystrophy Association | Not recruiting | 18 Years | N/A | All | 28 | Phase 2 | United States |
233 | NCT00982150 | September 2009 | 19 February 2015 | Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) | A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Talampanel | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 80 Years | Both | 446 | Phase 2 | United States;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain | |
234 | JPRN-UMIN000002276 | 2009/08/01 | 2 April 2019 | Developmental research of communication devices based on the brain machine interface using electroencephalograms | amyotrophic lateral sclerosis | Let the patients use the communication devices to select characters on a computer monitor as they intend by recording EEG. | Osaka University | Not Recruiting | 20years-old | Not applicable | Male and Female | 10 | Not applicable | Japan | ||
235 | NCT00931944 | July 2009 | 8 January 2018 | Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211) | An Open-Label, Safety and Tolerability, Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: KNS-760704 | Knopp Biosciences | Not recruiting | 21 Years | 80 Years | All | 74 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
236 | NCT00965497 | July 2009 | 19 October 2017 | Escitalopram (Lexapro) for Depression MS or ALS | An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis | Major Depression;Multiple Sclerosis;Amyotrophic Lateral Sclerosis | Drug: escitalopram | University of South Carolina | Not recruiting | 18 Years | 70 Years | All | 13 | Phase 3 | United States | |
237 | EUCTR2008-007320-25-DE | 24/06/2009 | 3 April 2012 | Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole | Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole | ALS is a fatal neuromuscular disorder causing progressive loss of nervous control of voluntary muscles because of destruction of motor neurons in the brain and spinal cord.Riluzole is the only approved drug therapy that has been shown to prolong survival of ALS patients but its efficacy is limited.Consequently, there is a strong medical need to identify other compounds and to evaluate in clinical studies their potential to become a treatment of this devastating disease. MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Product Code: TRO19622 Pharmaceutical Form: Capsule, soft INN or Proposed INN: olesoxime CAS Number: 2203-87-0 Current Sponsor code: TRO19622 Other descriptive name: 4-cholesten-3-one, oxime Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 165- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | TROPHOS SA | Not Recruiting | Female: yes Male: yes | 470 | Phase 2/3 | United Kingdom;Germany;Belgium;France;Spain | |||
238 | EUCTR2008-006722-34-IT | 23/06/2009 | 19 March 2012 | Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS Lithium | Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS Lithium | Amyotrophic Lateral Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: CARBOLITHIUM Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lithium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | ISTITUTO SUPERIORE DI SANITA` | Not Recruiting | Female: yes Male: yes | Italy | |||||
239 | EUCTR2008-006224-61-ES | 12/06/2009 | 19 March 2012 | Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica | Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica | Esclerosis Lateral Amiotrófica MedDRA version: 9 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: PLENUR Pharmaceutical Form: Tablet INN or Proposed INN: LITIO CARBONATO CAS Number: 554-13-2 Other descriptive name: LITHIUM CARBONATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not Recruiting | Female: yes Male: yes | Spain | |||||
240 | NCT00925847 | June 2009 | 19 February 2015 | Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis | Open Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLA | Amyotrophic Lateral Sclerosis | Drug: lithium | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 23 | Phase 2 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
241 | NCT01384162 | June 2009 | 8 February 2016 | An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis | An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump | Amyotrophic Lateral Sclerosis | Drug: sNN0029 | Newron Sweden AB | Medtronic;ICON Clinical Research | Not recruiting | 18 Years | 75 Years | Both | 15 | Phase 1/Phase 2 | Belgium |
242 | EUCTR2008-005106-38-ES | 14/05/2009 | 19 March 2012 | ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELA | ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELA | Esclerosis Lateral Amiotrofica MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: PLENUR Pharmaceutical Form: Tablet INN or Proposed INN: LITIO CARBONATO CAS Number: 554-13-2 Other descriptive name: LITHIUM CARBONATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Lucia Galan Hospital Clinico San Carlos | Not Recruiting | Female: yes Male: yes | 280 | Spain | ||||
243 | NCT00875446 | May 13, 2009 | 16 December 2017 | First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis | A Single and Repeat Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of GSK1223249 in ALS Patients | Amyotrophic Lateral Sclerosis | Drug: PLACEBO;Drug: GSK1223249 | GlaxoSmithKline | Not recruiting | 18 Years | 80 Years | All | 76 | Phase 1 | United States;France;Italy;United Kingdom | |
244 | NCT00868166 | April 30, 2009 | 11 March 2019 | Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS | Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole | Amyotrophic Lateral Sclerosis | Drug: Olesoxime;Drug: Placebo Comparator;Drug: Riluzole | Hoffmann-La Roche | European Commission | Not recruiting | 18 Years | 80 Years | All | 512 | Phase 3 | Belgium;France;Germany;Spain;United Kingdom;Netherlands |
245 | NCT00886977 | April 2009 | 19 February 2015 | Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS) | Pilot-Study of YAM80 in Amyotrophic Lateral Sclerosis. Evaluation of the Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: YAM80 | Yoshino Neurology Clinic | Not recruiting | 25 Years | 65 Years | Both | 25 | Phase 2 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
246 | EUCTR2009-010060-41-IT | 24/02/2009 | 19 March 2012 | Evaluation of efficacy of lithium salts therapy in patients with Amyotrophic Lateral Sclerosis. - ND | Evaluation of efficacy of lithium salts therapy in patients with Amyotrophic Lateral Sclerosis. - ND | Amyotrophic Lateral Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: LITIO CARBONATO Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lithium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Trade Name: RILUTEK Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Riluzole Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | AZIENDA OSPEDALIERA PISANA | Not Recruiting | Female: yes Male: yes | Italy | |||||
247 | JPRN-UMIN000008527 | 2009/01/01 | 2 April 2019 | Study of efficacy and safety of NDDPX08 in ALS patients | Amyotrophic Lateral Sclerosis | For patients who begin to receive Rilutek treatment at the start or 4 weeks before the start of the observation period, the 12-week treatment with Rilutek alone (100 mg/day) during the observation period is followed by combined treatment (Rilutek + NDDPX08). The NDDPX08 dose level begins at 1.25 mg/day and is increased in steps to 15 mg/day during the 12-week treatment period according to the dose escalation schedule given on the next page (Fig. 1). If any serious adverse reaction arises following a dose increase to 10 mg/day and it is judged to be difficult to maintain this dose level, the dose level of 7.5 mg/day is regarded as the maintenance dose level. If alleviation of symptoms is noted during dose escalation steps, the dose level producing alleviation of symptoms is used as the maintenance dose level. The total NDDPX08 treatment period is 58-90 weeks (including the 4 weeks during which the dose level is reduced in steps). Follow-up of adverse events is continued until 1 month after the end of NDDPX08 treatment. Placebo (lactose) is administered to 10 of the 50 subjects planned to be enrolled in the study. | FeGALS | Not Recruiting | 20years-old | 75years-old | Male and Female | 50 | Not selected | Japan | ||
248 | NCT00706147 | January 2009 | 21 January 2019 | Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis | Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Arimoclomol;Drug: Placebo | University of Miami | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 38 | Phase 2/Phase 3 | United States |
249 | NCT00818389 | January 2009 | 19 October 2017 | Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Lithium Carbonate;Drug: Riluzole;Drug: placebo | Massachusetts General Hospital | ALS Association;ALS Society of Canada;National Institute of Neurological Disorders and Stroke (NINDS);University of Toronto;State University of New York - Upstate Medical University;Columbia University;University of Kentucky | Not recruiting | 18 Years | N/A | All | 84 | Phase 2/Phase 3 | United States;Canada |
250 | NCT00800501 | December 2008 | 19 February 2015 | A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis | A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump | Amyotrophic Lateral Sclerosis | Drug: sNN0029;Drug: Placebo | Newron Sweden AB | Medtronic;ICON Clinical Research | Not recruiting | 18 Years | 75 Years | Both | 18 | Phase 1/Phase 2 | Belgium |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
251 | NCT01984814 | December 2008 | 5 November 2018 | Stem Cell Therapy for Amyotrophic Lateral Sclerosis | The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on the Survival Duration in Amyotrophic Lateral Sclerosis - A Retrospective Control Study | Amyotrophic Lateral Sclerosis | Biological: Stem cell | Neurogen Brain and Spine Institute | Not recruiting | 26 Years | 76 Years | All | 0 | Phase 2 | India | |
252 | NCT02242071 | December 2008 | 5 November 2018 | Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis | The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on Motor Neuron Disease/Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: Stem Cell | Neurogen Brain and Spine Institute | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 1 | India | |
253 | EUCTR2007-003775-39-DE | 29/10/2008 | 3 June 2013 | Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis - Olanzapin in treatment of ALS-related appetite loss | Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis - Olanzapin in treatment of ALS-related appetite loss | patients with amyotrophic lateral sclerosis | Trade Name: Zyprexa Pharmaceutical Form: Tablet INN or Proposed INN: OLANZAPINE CAS Number: 132539061 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Charité – Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | Germany | |||||
254 | EUCTR2008-002062-62-NL | 14/10/2008 | 19 March 2012 | A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS) | A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic lateral sclerosis (ALS). MedDRA version: 9.1 Level: PT Classification code 10052653 Term: Amyotrophic lateral sclerosis gene carrier | Product Name: talampanel Product Code: TV-7110 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available yet CAS Number: 161832-65-1 Current Sponsor code: TV-7110 Other descriptive name: talampanel Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5 and 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: talampanel Product Code: TV-7110 Pharmaceutical Form: Capsule* INN or Proposed INN: Not available yet CAS Number: 161832-65-1 Current Sponsor code: TV-7110 Other descriptive name: talampanel Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5 and 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Teva Pharmaceutical Industries, Ltd | Not Recruiting | Female: yes Male: yes | 540 | Hungary;Germany;Netherlands;Belgium;France;Spain;Italy | ||||
255 | EUCTR2008-003707-32-FR | 09/10/2008 | 19 March 2012 | Etude de l'effet du carbonate de lithium sur une population de patients atteints de SLA en ouvert en comparaison avec une population de référence. LISLA - LISLA | Etude de l'effet du carbonate de lithium sur une population de patients atteints de SLA en ouvert en comparaison avec une population de référence. LISLA - LISLA | Patient atteint de sclérose latérale amyotrophique. MedDRA version: 8.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: Téralithe LP Product Name: Téralithe LP Pharmaceutical Form: Tablet INN or Proposed INN: Carbonate de lithium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | France | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
256 | EUCTR2008-002110-22-NL | 16/09/2008 | 19 March 2012 | A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS | A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS | Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months. MedDRA version: 9.1 Level: LLT Classification code 10052889 Term: ALS | Trade Name: Lithiumcarbonaat 400 PCH tabletten Product Name: Lithiumcarbonaat Pharmaceutical Form: Tablet CAS Number: 554132 Other descriptive name: LITHIUM CARBONATE Concentration unit: g gram(s) Concentration type: equal Concentration number: 400-400 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Prof. dr L.H. van den Berg, UMC-Utrecht | Not Recruiting | Female: yes Male: yes | Netherlands | |||||
257 | NCT00696332 | September 2008 | 19 February 2015 | Talampanel for Amyotrophic Lateral Sclerosis (ALS) | A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects With Amyotrophic Lateral Sclerosis (ALS) | ALS | Drug: Talampanel;Other: placebo | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 80 Years | Both | 559 | Phase 2 | United States;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain | |
258 | NCT00748501 | September 2008 | 19 February 2015 | Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: SB-509 | Sangamo Biosciences | Not recruiting | 18 Years | 85 Years | Both | 45 | Phase 2 | United States | |
259 | NCT00694941 | June 2008 | 19 February 2015 | A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS) | A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: ONO-2506PO | Ono Pharmaceutical Co. Ltd | Not recruiting | 18 Years | N/A | Both | 15 | Phase 2 | Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom | |
260 | NCT00919555 | June 2008 | 19 February 2015 | Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) | Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Pioglitazone and Tretinoin;Drug: Tretinoin and Pioglitazone HCL;Drug: Placebo | Phoenix Neurological Associates, LTD | Not recruiting | 18 Years | 85 Years | Both | 28 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
261 | EUCTR2007-004723-37-DE | 16/05/2008 | 19 March 2012 | A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). | A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Product Name: ONO-2506PO Product Code: ONO-2506PO Pharmaceutical Form: Capsule, soft INN or Proposed INN: Arundic Acid CAS Number: 185517-21-9 Current Sponsor code: ONO-2506PO Other descriptive name: (2R)-2-Propyloctanoic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | ONO Pharmaceutical Co., Ltd. | Not Recruiting | Female: yes Male: yes | 273 | Phase 2 | United Kingdom;Germany;Belgium;France | |||
262 | NCT00790582 | May 2008 | 19 February 2015 | A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: lithium carbonate | Forbes Norris MDA/ALS Research Center | Muscular Dystrophy Association | Not recruiting | 21 Years | 80 Years | Both | 100 | Phase 2 | United States |
263 | EUCTR2006-005410-13-DE | 22/04/2008 | 4 February 2013 | EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE). | EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE). | Male or female adult patients with amyotrophic lateral sclerosis (ALS) accoring to the El Escorial Criteria for the diognosis of ALS and treated for at least 3 month with 100 mg riluzole (standard therapy). MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: Actos 15 mg Pharmaceutical Form: Tablet INN or Proposed INN: Pioglitazone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Actos 30 mg Pharmaceutical Form: Tablet INN or Proposed INN: Pioglitazone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Actos 45 mg Pharmaceutical Form: Tablet INN or Proposed INN: Pioglitazone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University Hospital of Ulm | Not Recruiting | Female: yes Male: yes | Germany | |||||
264 | EUCTR2008-001094-15-IT | 10/03/2008 | 19 March 2012 | SINGLE-BLIND, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING TRIAL ON LITHIUM FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) - ND | SINGLE-BLIND, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING TRIAL ON LITHIUM FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) - ND | ALS patient according with the El-Escorial criteria MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: CARBOLITHIUM*100CPS 150MG Pharmaceutical Form: Tablet INN or Proposed INN: Lithium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | Authorised | Female: yes Male: yes | Italy | |||||
265 | NCT00647296 | March 2008 | 8 January 2018 | Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) | A 2-Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: KNS-760704;Drug: Placebo | Knopp Biosciences | Not recruiting | 21 Years | 80 Years | All | 102 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
266 | EUCTR2007-001592-10-IT | 15/02/2008 | 19 March 2012 | A randomized, double-blind pilot study vs. placebo for the evaluation of efficacy and tolerability of tauroursodeoxycholic acid administered by oral route as add on treatment in patients affected by amyotrophic lateral sclerosis. - TUDCA-ALS | A randomized, double-blind pilot study vs. placebo for the evaluation of efficacy and tolerability of tauroursodeoxycholic acid administered by oral route as add on treatment in patients affected by amyotrophic lateral sclerosis. - TUDCA-ALS | AMYOTROPHIC LATERAL SCLEROSIS MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Product Name: Tauroursodeoxycholic acid Pharmaceutical Form: Prolonged-release capsule, hard INN or Proposed INN: Tauroursodeoxycholic acid Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Prolonged-release capsule, hard Route of administration of the placebo: Oral use | ISTITUTO NEUROLOGICO CARLO BESTA | Authorised | Female: yes Male: yes | Italy | |||||
267 | NCT00445172 | February 2008 | 16 December 2017 | A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: E0302 (mecobalamin) | Eisai Co., Ltd. | Not recruiting | 20 Years | N/A | All | 135 | Phase 2/Phase 3 | Japan | |
268 | EUCTR2007-002117-39-ES | 31/01/2008 | 19 March 2012 | MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICA MEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS | MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICA MEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS | Esclerosis Lateral Amiotrofica Amyotrophic lateral Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: EBIXA Pharmaceutical Form: Tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE CAS Number: 41100-52-1 Current Sponsor code: EU/1/02/219/007-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 99%- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Jorge Matias-Guiu Guia | Authorised | Female: yes Male: yes | 140 | Spain | ||||
269 | NCT00561366 | January 2008 | 19 February 2015 | A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS | A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Placebo;Drug: Arimoclomol | CytRx | Not recruiting | 18 Years | N/A | Both | 0 | Phase 2 | United States;Canada | |
270 | NCT00753571 | January 2008 | 19 February 2015 | Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response | Cistanche Total Glycosides Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response | Amyotrophic Lateral Sclerosis | Drug: Cistanche Total Glycosides | Peking University | Recruiting | 18 Years | 65 Years | Both | 40 | Phase 2 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
271 | NCT00573443 | December 2007 | 16 December 2017 | Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) | Pseudobulbar Affect (PBA) | Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: Placebo | Avanir Pharmaceuticals | INC Research | Not recruiting | 18 Years | 80 Years | All | 326 | Phase 3 | United States;Argentina;Brazil |
272 | EUCTR2007-004165-17-IT | 25/09/2007 | 19 March 2012 | Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis. - ND | Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis. - ND | Amyotrophic lateral sclerosis (ALS) MedDRA version: 6.1 Level: PT Classification code 10002026 | Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Ceftriaxone Concentration unit: g gram(s) Concentration type: equal Concentration number: 2- | AZIENDA OSPEDALIERA PISANA | Not Recruiting | Female: yes Male: yes | Italy | |||||
273 | NCT00600873 | August 2007 | 19 February 2015 | R(+)PPX High Dose Treatment of ALS | Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | Not recruiting | 30 Years | 80 Years | Both | 10 | Phase 1/Phase 2 | United States | |
274 | EUCTR2007-002379-16-IT | 29/05/2007 | 17 February 2014 | MULTICENTER TRIAL (SINGLE BLIND)VS ON THE EFFICACY OF LITHIUM SALTS +RILUZOLE VS PLACEBO+RILUZOLE IN PATIENTS AFFECTED BY AMYOTROPHIC LATERAL SCLEROSIS - EFFICACY OF LITHIUM IN ALS | MULTICENTER TRIAL (SINGLE BLIND)VS ON THE EFFICACY OF LITHIUM SALTS +RILUZOLE VS PLACEBO+RILUZOLE IN PATIENTS AFFECTED BY AMYOTROPHIC LATERAL SCLEROSIS - EFFICACY OF LITHIUM IN ALS | Patients affected by amyotrophic lateral sclerosis (ALS) MedDRA version: 6.1 Level: PT Classification code 10002026 | Trade Name: CARBOLITHIUM Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lithium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX | Not Recruiting | Female: yes Male: yes | Italy | |||||
275 | NCT00444613 | April 2007 | 19 February 2015 | A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: E0302 (mecobalamin);Drug: Placebo | Eisai Co., Ltd. | Not recruiting | 20 Years | N/A | Both | 373 | Phase 2/Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
276 | NCT00409721 | March 2007 | 19 February 2015 | The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS) | A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS | Amyotrophic Lateral Sclerosis | Drug: Memantine | University of Alberta | ALS Association | Not recruiting | 18 Years | 80 Years | Both | 42 | Phase 2 | Canada |
277 | NCT00635960 | March 2007 | 19 February 2015 | Growth Hormone in Amyotrophic Lateral Sclerosis | Efficacy, Safety and Tolerability of Growth Hormone in Patients With Amyotrophic Lateral Sclerosis as add-on Therapy to Riluzole | Amyotrophic Lateral Sclerosis | Drug: Growth Hormone (Somatropin);Drug: Placebo | Federico II University | Istituto Biostrutture e Immagini, CNR Naples;Agenzia Italiana del Farmaco | Not recruiting | 40 Years | 85 Years | Both | 40 | Phase 2 | Italy |
278 | EUCTR2006-002660-26-GB | 08/01/2007 | 19 March 2012 | A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION | A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION | Amyotrophic Lateral Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Product Name: ONO-2506PO Product Code: ONO-2506PO Pharmaceutical Form: Capsule, soft INN or Proposed INN: Arundic Acid CAS Number: 185517-21-9 Current Sponsor code: ONO-2506 Other descriptive name: (2R)-2-Propyloctanoic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | ONO Pharmaceutical Co.,Ltd | Not Recruiting | Female: yes Male: yes | 392 | Germany;United Kingdom;Netherlands;Belgium;France;Italy;Austria | ||||
279 | NCT00424463 | January 2007 | 19 February 2015 | Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) | An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3) | Amyotrophic Lateral Sclerosis (ALS) | Drug: MCI-186;Drug: Placebo of MCI-186 | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 20 Years | N/A | Both | 181 | Phase 3 | Japan | |
280 | NCT00372879 | December 2006 | 11 April 2016 | Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS | Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. | Amyotrophic Lateral Sclerosis | Dietary Supplement: Vitamin E | Lawson Health Research Institute | Not recruiting | 18 Years | N/A | Both | 32 | Phase 3 | Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
281 | NCT00397423 | December 2006 | 19 February 2015 | G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response | Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response | Amyotrophic Lateral Sclerosis | Drug: Granulocyte Colony Stimulating Factor;Drug: NS | Peking University | Not recruiting | 18 Years | 65 Years | Both | 40 | Phase 2 | China | |
282 | NCT00415519 | December 2006 | 19 February 2015 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III | An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner | Amyotrophic Lateral Sclerosis (ALS) | Drug: MCI-186;Drug: Placebo of MCI-186 | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 20 Years | 75 Years | Both | 25 | Phase 3 | Japan | |
283 | EUCTR2006-002660-26-BE | 13/11/2006 | 19 March 2012 | A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION | A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION | Amyotrophic Lateral Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Product Name: ONO-2506PO Product Code: ONO-2506PO Pharmaceutical Form: Capsule, soft INN or Proposed INN: Arundic Acid CAS Number: 185517-21-9 Current Sponsor code: ONO-2506 Other descriptive name: (2R)-2-Propyloctanoic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | ONO Pharmaceutical Co.,Ltd | Not Recruiting | Female: yes Male: yes | 392 | Germany;United Kingdom;Netherlands;Belgium;France;Italy;Austria | ||||
284 | NCT00403104 | November 2006 | 19 February 2015 | Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Multi-centre, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Investigate Efficacy and Safety of ONO-2506PO Compared to Placebo, in the Presence of Riluzole, to Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS), Who Have Had Onset of Muscle Weakness Within 14 Months of Randomization | Amyotrophic Lateral Sclerosis (ALS) | Drug: ONO-2506PO | Ono Pharmaceutical Co. Ltd | Not recruiting | 18 Years | 74 Years | Both | 420 | Phase 2 | Austria;Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom | |
285 | EUCTR2006-001688-49-GB | 14/08/2006 | 19 March 2012 | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | Early stage of amyotrophic lateral sclerosis (ALS) MedDRA version: 8.1 Level: PT Classification code 10002026 | Product Name: 40 mg glatiramer acetate Product Code: 40 mg GA Pharmaceutical Form: Solution for injection CAS Number: 147245-92-9 Current Sponsor code: 40 mg GA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | TEVA Pharmaceutical Industries. Ltd. | Authorised | Female: yes Male: yes | 366 | Germany;United Kingdom;Belgium;Italy | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
286 | NCT00326625 | July 31, 2006 | 26 February 2018 | Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) | A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: 40 mg glatiramer acetate;Drug: Placebo | Teva Pharmaceutical Industries, Ltd. | Not recruiting | 18 Years | 70 Years | All | 366 | Phase 2 | Belgium;France;Germany;Israel;Italy;United Kingdom | |
287 | NCT00349622 | July 2006 | 19 October 2017 | Clinical Trial Ceftriaxone in Subjects With ALS | Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis;ALS | Drug: ceftriaxone;Other: placebo | Massachusetts General Hospital | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 513 | Phase 3 | United States;Canada;Puerto Rico |
288 | NCT00355576 | July 2006 | 19 February 2015 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Celecoxib;Drug: Creatine;Drug: Minocycline | Columbia University | ALS Association;Pfizer | Not recruiting | 21 Years | 85 Years | Both | 86 | Phase 2 | United States |
289 | NCT00324454 | May 2006 | 19 February 2015 | Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease | A Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease | Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy | Biological: Levetiracetam | Duke University | UCB Pharma | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United States |
290 | NCT00330681 | May 2006 | 16 December 2017 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner. | Amyotrophic Lateral Sclerosis (ALS) | Drug: MCI-186;Drug: Placebo of MCI-186 | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 20 Years | 75 Years | All | 206 | Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
291 | EUCTR2005-005152-40-IT | 19/04/2006 | 19 March 2012 | MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS | MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS | ALS MedDRA version: 6.1 Level: PT Classification code 10002026 | Product Name: ALPHA-LIPOIC ACID Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Tioctic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | Authorised | Female: yes Male: yes | 84 | Italy | ||||
292 | NCT00231140 | December 2005 | 19 February 2015 | Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) | Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Thalidomide (drug) | Charite University, Berlin, Germany | Not recruiting | 25 Years | 80 Years | Both | 40 | Phase 2 | Germany | |
293 | NCT00244244 | October 2005 | 19 February 2015 | A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS | A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: arimoclomol | CytRx | Not recruiting | 18 Years | N/A | Both | 80 | Phase 2 | United States | |
294 | NCT00596115 | October 2005 | 19 February 2015 | Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day | Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | University of Pittsburgh;University of Nebraska | Not recruiting | 30 Years | 80 Years | Both | N/A | ||
295 | EUCTR2005-003248-75-IT | 31/08/2005 | 19 March 2012 | PILOT STUDY ON SAFETY AND TOLERABILITY OF REPEATED MOBILIZATION PROCEDURES OF OSTEO-MEDULLARY DERIVED CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS | PILOT STUDY ON SAFETY AND TOLERABILITY OF REPEATED MOBILIZATION PROCEDURES OF OSTEO-MEDULLARY DERIVED CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS | SLOWING OF ALS PROGRESSION MedDRA version: 6.1 Level: PT Classification code 10002026 | Trade Name: MYELOSTIM 34*1FL 263MCG+1SIR Pharmaceutical Form: Powder and solvent for suspension for injection INN or Proposed INN: Lenograstim CAS Number: 135968-09-1 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 5- | AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | Authorised | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
296 | EUCTR2005-005873-31-IT | 01/08/2005 | 19 March 2012 | A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Lateral Sclerosis ALS - ND | A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Lateral Sclerosis ALS - ND | Amiotrophic Lateral Sclerosis MedDRA version: 6.1 Level: PT Classification code 10002026 | Trade Name: EPREX IV SC 1FL 1ML 40000 UI Pharmaceutical Form: Solution for infusion INN or Proposed INN: Erythropoietin CAS Number: 113427-24-0 Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | ISTITUTO NEUROLOGICO CARLO BESTA | Not Recruiting | Female: yes Male: yes | 20 | Italy | ||||
297 | NCT00140218 | August 2005 | 19 February 2015 | R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | University of Pittsburgh | Not recruiting | 21 Years | 85 Years | Both | 30 | Phase 1/Phase 2 | United States |
298 | NCT00353665 | July 2005 | 19 February 2015 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Memantine (Ebixa);Drug: riluzole;Drug: Placebo | University of Lisbon | H. Lundbeck A/S | Not recruiting | 20 Years | 75 Years | Both | 63 | Phase 2/Phase 3 | Portugal |
299 | NCT01020331 | June 2005 | 19 February 2015 | Memantine Therapy in Amyotrophic Lateral Sclerosis | Phase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALS | Amyotrophic Lateral Sclerosis | Drug: Memantine | Phoenix Neurological Associates, LTD | Forest Laboratories | Not recruiting | 18 Years | 85 Years | Both | 20 | Phase 2 | United States |
300 | EUCTR2004-004158-23-IT | 15/04/2005 | 19 March 2012 | DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) - ND | DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) - ND | Amyotrophic lateral sclerosis therapy MedDRA version: 9.1 Level: LLT Classification code 10002026 Term: Amyotrophic lateral sclerosis | Trade Name: ZIBREN*20BUST 500MG Pharmaceutical Form: Oral powder INN or Proposed INN: Acetylcarnitine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- | IST. DI RICERCHE FARMACOLOG. M. NEGRI | Not Recruiting | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
301 | NCT00107770 | April 2005 | 19 February 2015 | Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis) | Safety and Dose Escalating Study of Oral Sodium Phenylbutyrate in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: sodium phenylbutyrate | Department of Veterans Affairs | Muscular Dystrophy Association | Not recruiting | 18 Years | N/A | Both | 40 | Phase 1/Phase 2 | United States |
302 | NCT00136110 | April 2005 | 19 February 2015 | Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS | Amyotrophic Lateral Sclerosis | Drug: Sodium Valproate | UMC Utrecht | Princess Beatrix Fund, The Netherlands | Not recruiting | 18 Years | 85 Years | Both | 165 | Phase 3 | Netherlands |
303 | NCT00243932 | April 2005 | 19 October 2017 | Clinical Trial of High Dose CoQ10 in ALS | Clinical Trial of High Dose CoQ10 in ALS | Amyotrophic Lateral Sclerosis;Lou Gehrig's Disease | Drug: coenzyme Q10;Drug: Placebo | Columbia University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 21 Years | 85 Years | All | 185 | Phase 2 | United States |
304 | NCT00812851 | April 2005 | 19 February 2015 | Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) | Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) | Cramps;Amyotrophic Lateral Sclerosis | Drug: Dronabinol | Cantonal Hospital of St. Gallen | ALS Association | Not recruiting | 18 Years | N/A | Both | 24 | N/A | Switzerland |
305 | NCT00140452 | February 2005 | 19 February 2015 | Phase II Study Using Thalidomide for the Treatment of ALS | Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;ALS | Drug: Thalidomide | Dartmouth-Hitchcock Medical Center | Celgene Corporation | Not recruiting | 18 Years | 80 Years | Both | 24 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
306 | EUCTR2004-002855-15-DE | 29/12/2004 | 18 April 2012 | A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis. | A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis. | Amyotrophic Lateral Sclerosis | Product Code: TCH346 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not established CAS Number: 200189-97-5 Current Sponsor code: TCH346 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0, 2.5, 7.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 480 | United Kingdom;Germany;Italy | ||||
307 | EUCTR2004-002390-23-DE | 24/11/2004 | 19 March 2012 | Evaluation of the pharmacokinetic profile of Riluzole (XRP4274) and RPR112512 following multiple oral administrations of XRP4274 for 8 days in healthy Japanese and Caucasian male subjects | Evaluation of the pharmacokinetic profile of Riluzole (XRP4274) and RPR112512 following multiple oral administrations of XRP4274 for 8 days in healthy Japanese and Caucasian male subjects | amyotrophic lateral sclerosis Classification code 10002026 | Trade Name: RILUTEK Product Name: RILUTEK 50 mg, film-coated tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: riluzole Current Sponsor code: XRP4274 Concentration unit: mg milligram(s) Concentration number: 50- | Aventis Pharma Ltd. | Not Recruiting | Female: Male: yes | Germany | |||||
308 | NCT00230074 | November 2004 | 19 February 2015 | A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) | A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) | Amyotrophic Lateral Sclerosis | Drug: TCH346 | Novartis | Not recruiting | 21 Years | 80 Years | Both | 350 | Phase 2 | United States | |
309 | EUCTR2004-002912-27-ES | 04/10/2004 | 19 March 2012 | Open-Label Extension Study to Investigate the Continued Safety and Effect of ONO 2506PO (1200 mg OD). | Open-Label Extension Study to Investigate the Continued Safety and Effect of ONO 2506PO (1200 mg OD). | Amyotrophic lateral sclerosis MedDRA version: 7.0 Level: LL 1 Classification code 10002026 | Product Name: ONO-2506PO Product Code: ONO-2506PO Pharmaceutical Form: Capsule, soft INN or Proposed INN: (R)-(-)-2-Propyloctaroic acid Current Sponsor code: ONO-2506PO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | ONO PHARMA UK LTD | Authorised | Female: yes Male: yes | 500 | Spain | ||||
310 | NCT00072709 | September 2003 | 19 February 2015 | Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: TCH346 | Novartis Pharmaceuticals | Not recruiting | 21 Years | 80 Years | Both | 551 | Phase 2 | United States;Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
311 | NCT00125203 | July 2003 | 19 February 2015 | Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;Sialorrhea | Drug: Botulinum toxin type B (Myobloc);Procedure: Injection of salivary glands | The University of Texas Health Science Center at San Antonio | ALS Association;University of Kansas;Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System | Not recruiting | 21 Years | 85 Years | Both | 20 | Phase 2/Phase 3 | United States |
312 | NCT00035815 | June 2003 | 19 October 2017 | Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial | Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Insulin like growth factor, type 1;Drug: Placebo | Mayo Clinic | National Institute of Neurological Disorders and Stroke (NINDS);ALS Association;Cephalon | Not recruiting | 18 Years | 80 Years | All | 330 | Phase 3 | United States;Puerto Rico |
313 | NCT00069186 | June 2003 | 19 February 2015 | Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis | A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis (ALS) | Drug: Creatine Monohydrate | The Avicena Group | Not recruiting | 21 Years | 80 Years | Both | 107 | Phase 3 | United States | |
314 | NCT00047723 | January 2003 | 19 February 2015 | Minocycline to Treat Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: minocycline | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 21 Years | 85 Years | Both | 400 | Phase 3 | United States | ||
315 | NCT00070993 | December 2002 | 19 February 2015 | Creatine for the Treatment of Amyotrophic Lateral Sclerosis | Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: creatine monohydrate | National Center for Complementary and Integrative Health (NCCIH) | Office of Dietary Supplements (ODS) | Not recruiting | 21 Years | 80 Years | Both | 110 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
316 | NCT00036413 | January 2002 | 19 February 2015 | A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis | A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Safety and Dose-ranging Study of Three Oral Doses (0.5 mg, 2.5 mg and 10 mg Once Daily) of TCH346 in Patients With Amyotrophic Lateral Sclerosis. | Amyotrophic Lateral Sclerosis | Drug: TCH346 | Novartis Pharmaceuticals | Not recruiting | 40 Years | 75 Years | Both | 44 | Phase 2 | United States | |
317 | NCT00021697 | January 2001 | 8 August 2016 | Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS | A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: AVP-923 | Avanir Pharmaceuticals | Not recruiting | 18 Years | 80 Years | Both | 100 | Phase 3 | United States | |
318 | NCT00214110 | January 2001 | 12 October 2015 | Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] | Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS] | Amyotrophic Lateral Sclerosis (ALS) | Drug: Tamoxifen | University of Wisconsin, Madison | Not recruiting | 18 Years | 90 Years | Both | 100 | Phase 2 | United States | |
319 | NCT00542412 | January 2001 | 19 February 2015 | CARE Canadian ALS Riluzole Evaluation | Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls | Amyotrophic Lateral Sclerosis | Drug: Riluzole | Sanofi | Not recruiting | 18 Years | 75 Years | Both | 414 | Phase 4 | Canada | |
320 | NCT00005674 | May 2000 | 19 February 2015 | Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS] | Amyotrophic Lateral Sclerosis | Drug: Creatine | National Center for Research Resources (NCRR) | Muscular Dystrophy Association | Not recruiting | 18 Years | 80 Years | Both | Phase 2 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
321 | NCT00005766 | May 2000 | 19 February 2015 | Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Creatinine | National Center for Research Resources (NCRR) | Not recruiting | 18 Years | 80 Years | Both | Phase 2 | United States | |||
322 | NCT00004771 | October 1992 | 19 February 2015 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | Spinal Muscular Atrophy;Amyotrophic Lateral Sclerosis;Spinobulbar Muscular Atrophy | Drug: leuprolide;Drug: testosterone | National Center for Research Resources (NCRR) | Ohio State University | Not recruiting | 18 Years | N/A | Male | 40 | Phase 2 |